US20110178318A1 - Methods of making bimetal complexes - Google Patents
Methods of making bimetal complexes Download PDFInfo
- Publication number
- US20110178318A1 US20110178318A1 US13/011,144 US201113011144A US2011178318A1 US 20110178318 A1 US20110178318 A1 US 20110178318A1 US 201113011144 A US201113011144 A US 201113011144A US 2011178318 A1 US2011178318 A1 US 2011178318A1
- Authority
- US
- United States
- Prior art keywords
- copper
- zinc
- acid
- silver
- coordination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YMXHTKKMLXGXDC-UHFFFAOYSA-N C=C(O)CC(=O)O Chemical compound C=C(O)CC(=O)O YMXHTKKMLXGXDC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/18—Azelaic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/20—Sebacic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/21—Dicarboxylic acids containing twelve carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/155—Citraconic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/08—Saturated compounds having a carboxyl group bound to a six-membered ring
- C07C61/09—Completely hydrogenated benzenedicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/14—Monocyclic dicarboxylic acids
- C07C63/15—Monocyclic dicarboxylic acids all carboxyl groups bound to carbon atoms of the six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/14—Monocyclic dicarboxylic acids
- C07C63/15—Monocyclic dicarboxylic acids all carboxyl groups bound to carbon atoms of the six-membered aromatic ring
- C07C63/16—1,2 - Benzenedicarboxylic acid
- C07C63/20—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/14—Monocyclic dicarboxylic acids
- C07C63/15—Monocyclic dicarboxylic acids all carboxyl groups bound to carbon atoms of the six-membered aromatic ring
- C07C63/24—1,3 - Benzenedicarboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/14—Monocyclic dicarboxylic acids
- C07C63/15—Monocyclic dicarboxylic acids all carboxyl groups bound to carbon atoms of the six-membered aromatic ring
- C07C63/26—1,4 - Benzenedicarboxylic acid
- C07C63/28—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic System
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
- C07F3/06—Zinc compounds
Definitions
- compositions that contain bimetal complexes can be prepared by reacting a polyfunctional compound with two or more coordination elements.
- Polycarboxylic acids are polyfunctional acids used in many products.
- the ion form of carboxylic acids, as well as its esters and salts, are known as carboxylates.
- Various copper carboxylates are known through the extensive use of the carboxylate ion in crystal engineering to explore the structural chemistry of copper (II) carboxylates, which exist, for example as copper (II) malonates, copper (II) coppergiutamates, copper citrates and other copper complexes known.
- compositions containing reaction products of polyfunctional carboxylic acid compounds with two or more coordination elements For example, it would be desirable to provide malonates having both copper and at least one other metallic constituent, such as zinc. These can be obtained by reacting a mixture of malonic and a 3:1:1 molar ratio with the metallic components resulting in the formation of greenish-blue copper II zinc II malonate crystals.
- Polyamines are polyfunctional bases used in many products. When combined with metallic constituent, the ion form of amines as well as their amides and salts, can produce amino complexes.
- Various copper amine complexes are used extensively in crystal engineering to explore the structural chemistry of amine complexes, such as, for example, copper (II) amine complexes. Copper (II) amine complexes exist in numerous forms, many of which have an intense blue color. For example, intense blue various copper (II) ethylenediamine complexes are known.
- compositions containing reactions products of polyfunctional amine compounds with two or more coordination elements For example, it would be desirable to provide amines complexes having both copper and at least one other metallic constituent, such as zinc.
- Poly-functional organic compounds having a carboxyl group and an amine group are known as amino acids.
- the ionic form of amino acids vary with the pH of the media, with ionic forms of the acid being known as carboxylates and the ionic forms of the amine as being known as ammonium complexes.
- compositions containing reaction products of amino acid compounds with two or more coordination elements For example, it would be also desirable to provide amino acid complexes having copper and at least one other metallic constituent, such as zinc. For example in a mixture of glutamic acid, zinc carbonate and copper carbonate in a 3:1:1 molar ratio results in the formation of greenish-blue crystals. It would be desirable to provide compositions containing reaction products of polyfunctional compounds with two or more coordination elements. It would also be desirable to provide glutamates having both copper and at least one other metallic constituent, such as zinc.
- compositions in accordance with the present disclosure contain a bimetal complex.
- the bimetal complex can be the reaction product of a polyfunctional compound with two or more coordination elements.
- the polyfunctional compound can be, for example, a polyfunctional acid or an amino acid.
- the coordination elements can be selected from the elements listed in Groups IIIA to VIIIA, Groups IB to IIIB, of periods 4 and 5 and aluminum in Group IIIB, period 3 of The Periodic Table of the Elements.
- bimetal complexes are made by 1) contacting one or more polyfunctional compounds with two or more coordination elements, wherein the molar ratio of polyfunctional compound to two or more coordination elements is at least 3:2; and 2) isolating the reaction product.
- copper-zinc malonate complexes are synthesized from malonic acid and copper and zinc constituents. Methods of making copper-zinc dual salts are also described. In embodiments, copper-zinc malonate compositions are made by:
- Excess malonic acid in the manufacturing process may drive the formation of copper-zinc malonates which precipitate in the reaction solution.
- reaction products of polyfunctional compounds with two or more coordination elements and compositions containing such reaction products are described.
- the polyfunctional compound can be any compound that contains at least two functional groups that may complex with metal cations in solution.
- the functional groups that may be present include carboxylic acid groups and amino groups.
- Suitable polyfunctional compounds include, but are not limited to polyfunctional acids, polyfunctional amines and amino acids. Other suitable polyfunctional compounds will be readily envisioned by those skilled in the art reading the present disclosure. It should of course be understood that mixtures of polyfunctional compounds may be used.
- Polyfunctional acids are primarily monomeric compositions having two or more carboxylic acid groups.
- Non-limiting examples of polyfunctional acids include maleic acid, fumaric acid, citraconic acid, itaconic acid, glutaconic acid, phthalic acid, isophthalic acid, terephthalic acid, cyclohexane dicarboxylic acid, succinic acid, adipic acid, sebacic acid, azealic acid, malonic acid, dodecanedioic acid, 1,18-octadecanedioic acid, dimer acids (prepared from a mono-, di- or triunsaturated fatty acid, acid wax, acid anhydride grafted wax, or other suitable polycarboxylic acid reacting compound), alkenyl succinic acids (such as n-dodecenylsuccinic acid, docecylcucinic acid and octadecenylsuccinic acid).
- the polyfunctional acid can be present in acid
- Amino acids may also be used as the polyfunctional compound.
- Amino acids are known to those skilled in the art and include at least a carboxylic acid functionality and an amino functionality. Suitable amino acids include naturally occurring amino acids and synthetic amino acids.
- Non-limiting examples of amino acids include, but are not limited to: glycine; aminopolycarboxylic acids (e.g., aspartic acid, ⁇ -hydroxyaspartic acid, glutamic acid, ⁇ -hydroxyglutamic acid, ⁇ -methylaspartic acid, ⁇ -methylglutamic acid, ⁇ , ⁇ -dimethylaspartic acid, ⁇ -hydroxyglutamic acid, ⁇ , ⁇ -dihydroxyglutamic acid, ⁇ -phenylglutamic acid, ⁇ -methyleneglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid); amino acid amides such as glutamine and asparagine; polyamino- or polybasic
- glycine alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline.
- Aminopolycarboxylic acids e.g., aspartic acid, ⁇ -hydroxyaspartic acid, glutamic acid, ⁇ -hydroxyglutamic acid, ⁇ -methylaspartic acid, ⁇ -methylglutamic acid, ⁇ , ⁇ -dimethylaspartic acid, ⁇ -hydroxyglutamic acid, ⁇ , ⁇ -dihydroxyglutamic acid, ⁇ -phenylglutamic acid, ⁇ -methyleneglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid. Polyaminoacids may also be used provided they form complexes with the coordination elements employed.
- the polyfunctional compound is reacted with two or more coordination elements.
- the coordination elements can be chosen from the elements listed in Groups IIIA to VIIIA, Groups IB to IIIB, of periods 4 and 5 and aluminum in Group IIIB, period 3 of The Periodic Table of the Elements. Suitable non-limiting examples of elements listed in group IB of The Periodic Table of Elements include copper, silver, and gold.
- Suitable non-limiting examples of coordination elements include aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, and indium. Tin may also be used. Those skilled in the are will readily envision suitable compounds for providing the coordination elements in solution.
- water soluble salts containing the coordination element may be used.
- the salts may be organic or inorganic.
- Suitable water-soluble silver salts include silver nitrate, silver acetate, silver propionate, silver sulfate, silver butyrate, silver isobutyrate, silver benzoate, silver tartrate, silver salicylate, silver malonate, silver succinate and silver lactate.
- Suitable water-soluble aluminum salts include aluminum potassium sulfate, aluminum chloride, aluminum sodium sulfate, aluminum sodium phosphate, aluminum sulfate, aluminum nitrate, and sodium aluminate.
- Suitable water-soluble copper salts include copper sulfate, fluoroborate, hydroxide, borate, fluoride, carbonate, oxychloride, formate or acetate.
- Suitable water-soluble zinc salts include zinc chloride, zinc bromide, zinc iodide, zinc chlorate, zinc bromate, zinc chlorite, zinc perchlorate, zinc sulfate, zinc nitrate, zinc nitrite, zinc borate, zinc metaborate, basic zinc borate, zinc hexafluorosilicate, zinc hypophosphite, zinc glycerophosphate, zinc bichromate, zinc citrate, zinc thionate, zinc dithionate, zinc tetrathionate, zinc pentathionate, zinc thiocyanate, zinc benzoate, zinc acetate, zinc salicylate, zinc picrate, zinc permanganate, zinc hydrogen phosphate, zinc formate, zinc ethylsulfate and zinc phenolsulfonate
- Suitable water soluble nickel salts examples include nickel sulfate hexahydrate and nickel chloride hexahydrate. It should be understood that the listed salts are only a small portion of the salts suitable for use in accordance with the present disclosure.
- inorganic salts are suitable provided that they provide coordination element cations when placed in an aqueous solution. Thus, the foregoing list of salts should be considered a non-limiting, illustrative list.
- a reaction solution can be prepared by mixing the various ingredients in water. Water in the mixture may advantageously be added in limited amounts sufficient to allow the reaction product to precipitate from solution upon formation. Accordingly, the reaction mixture is not so dilute as to prevent product precipitate formation. Where necessary, mixing and heating can be used to bring the reactants to 40-100° C. in order to solubilize the reactants. As a result, reactant solubility may be enhanced through energy input such as microwave heating or addition of boiling water. The input of the energy may take place through any instrument capable of heating the aqueous reaction mixture.
- the reaction products formed in solution may be immediately separated so that their production can take place in a continuous process. Where a short reaction time and rapid crystallization of the reaction product occur, the conversion may be carried out continuously, and the recovery of the resultant solid product may take place by any conventional manner such as filtering, centrifugation, or sedimentation.
- the polyfunctional compound is present in the reaction mixture in amounts that will contact metal cations in an aqueous solution. Suitable amounts of polyfunctional compound also include excess amounts in relation to the amount of metal cations. In embodiments, polyfunctional compound is present in a 3:1:1 molar ratio in relation to the metal constituents. In embodiments, the polyfunctional compound is malonic acid which can be present in acidic form, salt form, or mixtures thereof. In embodiments, the process parameters are especially advantageous if the polyfunctional compound is added to excess in comparison to the metal counter cation constituents. Depending on the desired complex, the latter are added so that the molar ratio of polyfunctional compound to metal ions is approximately 3:2.
- the coordination elements may be present as one or more ionic compounds formed by joining one or more independent coordination element molecules or ions of a first type and coordination element molecules or ions of a second type to a central unit by ionic bonds.
- the reaction product may be in the form of a trinuclear cation, where structurally independent coordination element hydrates are bridged by a central unit.
- the central unit may be a multi-membered ring such as eight-membered ring, six-membered ring, and four-membered metalocycle for bridging or chelating functions between the coordination element constituents. Accordingly, the crystal structures of the reaction products can be very diverse, from ionic to three-dimensional polymers.
- the reaction products are present in several hydrate, and polymorphic forms.
- suitable reaction products can be non-toxic bimetal complexes that include copper, zinc, aluminum and/or silver constituents.
- copper, zinc, aluminum and/or silver reaction products include, but are not limited to water soluble compounds that contain copper, zinc, aluminum and/or silver.
- Non-limiting examples of water-soluble bimetal complexes include copper-zinc citrate, copper-silver citrate, silver-zinc citrate, copper-zinc oxalate, copper-silver oxalate, silver-zinc oxalate, copper-zinc tartarate, copper-silver tartarate, silver-zinc tartarate, copper-zinc malate, copper-silver malate, silver-zinc malate, copper-zinc succinate, copper-silver succinate, silver-zinc succinate, copper-zinc malonate, copper-silver malonate, silver-zinc malonate, copper-zinc maleate, copper-silver maleate, silver-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate, copper-zinc maleate,
- copper, zinc, aluminum and silver salts of organic multi carboxylic acids are suitable for use in accordance with the present disclosure.
- suitable salts can be doped such that the unit cell of the salt has zinc or silver constituents dispersed therein. Such zinc or silver constituents may either substitute another metallic constituent or fill a preexisting void in the unit cell.
- suitable reaction products can be copper salts having zinc or silver constituents therein.
- zinc or silver may either substitute a copper constituent or fill a preexisting void in the copper salt's unit cell.
- Suitable non-limiting examples of copper salts which may be used to form bimetallic complexes include copper (II) malonate and any hydrated form thereof such as copper (II) malonate dihydrate, copper (II) malonate trihydrate, and copper malonate tetrahydrate.
- suitable non-limiting examples of suitable copper salt active ingredients include copper citrate, copper oxalate, copper tartarate, copper malate, copper succinate, copper malonate, copper maleate, copper aspartate, copper glutamate, copper glutarate, copper fumarate, copper glucarate, copper polyacrylic acid, and combinations thereof.
- suitable copper salts can be doped such that the unit cell of the salt has zinc or silver constituents dispersed therein. Such zinc or silver constituents may either substitute a copper constituent or fill a preexisting void in the unit cell.
- malonic acid may be reacted with salts containing copper and zinc constituents in an aqueous solution. It has been found that where the malonic acid, copper and zinc constituents are present in at least about a 3:1:1 molar ratio, copper-zinc malonates may be produced in good yield and high crystalline purity.
- Malonic acid refers to 1,3-propanedioic acid, a dicarboxylic acid with structure CH 2 (COOH) 2 or:
- malonates The ion form of malonic acid, as well as its esters and salts, are known as malonates.
- diethyl malonate is ethyl ester of malonic acid.
- copper-zinc malonate applies to any salt substances formed from malonic acid having copper and zinc constituents.
- Suitable ingredients for the formation of copper-zinc malonates include malonic acid, one or more bases of copper and zinc, and water.
- suitable salt forms provide copper and zinc cations capable of bonding to malonate anions.
- Other suitable ingredients for the formation of copper-zinc malonates will include the replacement of bases of copper and zinc with the metallic form of copper and zinc.
- the elemental form of copper and zinc are known as copper and zinc metals and will be dissolved in the acidic water media as they react with malonic acid.
- One or more salts containing copper and zinc constituents are present in amounts that will contact malonic acid in an aqueous solution.
- Suitable salts for making copper-zinc malonate compositions in accordance with this disclosure include metal salts containing complex-forming metal ions of copper and/or zinc.
- Non-limiting examples of suitable metal salts are copper (I) and (II) salts such as copper chloride, copper bromide, copper fluoride, copper nitrate, copper fluoroborate, copper sulfate, copper acetate, copper trifluoro acetate, copper stearate, copper octoate, copper methacrylate, copper malonate, copper benzoate; zinc salts such as zinc bromide, zinc chromate, zinc chloride, zinc stearate, zinc octoate, and zinc ethylhexoate.
- copper (I) and (II) salts such as copper chloride, copper bromide, copper fluoride, copper nitrate, copper fluoroborate, copper sulfate, copper acetate, copper trifluoro acetate, copper stearate, copper octoate, copper methacrylate, copper malonate, copper benzoate
- zinc salts such as zinc bromide, zinc chromate, zinc chloride,
- the aqueous solution may include one or more metallic salts, such as cupric carbonate (CuCO 3 .Cu(OH) 2 ), zinc carbonate (3Zn(OH) 2 .2ZnCO 3 ), metallic copper, metallic zinc and combinations thereof.
- metallic salts such as cupric carbonate (CuCO 3 .Cu(OH) 2 ), zinc carbonate (3Zn(OH) 2 .2ZnCO 3 ), metallic copper, metallic zinc and combinations thereof.
- Basic salts such as basic zinc salts, basic copper salts, and combinations thereof are also suitable for use in accordance with the present disclosure.
- suitable metal basic salts are: copper (I) and (II) salts such as copper carbonate, copper oxide, and copper hydroxide; and zinc salts such as zinc carbonate, zinc oxide, and zinc hydroxide.
- salts are only a small portion of the salts suitable for use in accordance with the present disclosure.
- inorganic salts are suitable provided that they provide copper and zinc cations when placed in an aqueous solution.
- the foregoing list of salts should be considered a non-limiting, illustrative list.
- the reaction solution can be prepared by mixing the various ingredients in water where malonic acid and the salts may ionize and become more reactive. Water in the mixture is added in limited amounts sufficient to allow copper-zinc malonates to precipitate from solution upon formation. Accordingly, the reaction mixture is not so dilute as to prevent product precipitate formation. Where copper and zinc salts in the reaction mixture are insoluble and form dispersions (such as at cooler temperatures), mixing and heating steps can be applied to bring the reactants to 40-100° C. in order to solubilize the reactants. As a result, reactant solubility may be enhanced through energy input such as microwave heating or addition of boiling water dissolver. The input of the energy may take place through any instrument capable of heating the aqueous reaction mixture.
- the copper-zinc malonate complexes formed in solution may be immediately separated so that their production can take place in a continuous process. Due to the short reaction time and the rapid crystallization of the copper-zinc malonate product, the conversion may be carried out continuously, and the recovery of the resultant solid product may take place by any conventional manner such as filtering, centrifugation, or sedimentation.
- the concentration of the polyfunctional compound and that of the copper and zinc constituents may be pre-selected so that the total concentration of product formed exceeds the solubility equilibrium. This will result in product precipitating from solution in solid form for easy collection.
- the final composition may be a deep blue crystal having good yield and substantial crystalline purity.
- Suitable copper-zinc malonate forms in accordance with the present disclosure include any salt formed from the neutralization of malonic acid by one or more copper containing molecules and one or more zinc containing molecules.
- Illustrative examples include salt formed by the neutralization of malonic acid by cupric carbonate (CuCO 3 .Cu(OH) 2 ), and zinc carbonate (3Zn(OH) 2 .2ZnCO 3 ) in an aqueous solution.
- copper may be added first, followed by zinc in order to obtain the salts of the present disclosure.
- the copper-zinc malonates may be one or more ionic compounds formed by joining one or more independent copper molecules or ions and one or more independent zinc molecules or ions to a central unit by ionic bonds.
- the copper-zinc malonate may be in the form of a trinuclear cation, where structurally independent copper and zinc hydrates are bridged by a central unit such as an octahedral diaquadimalonatocopper (II) unit.
- II octahedral diaquadimalonatocopper
- various coordination modes are possible depending on the source of the copper and zinc and synthesis conditions.
- the central unit malonate ion may be a multi-membered ring such as eight-membered ring, six-membered ring, and four-membered metalocycle for bridging or chelating functions between the copper and zinc constituents.
- the crystal structures of copper-zinc malonates can be very diverse, from ionic to three-dimensional polymers.
- the copper-zinc malonates can be found in several hydrate, and polymorphic forms.
- the process parameters are especially advantageous if the polyfunctional compound is added to excess in comparison to the metal counter cation constituents. Depending on the desired complex, the latter are added so that the molar ratio of polyfunctional compound to metal ions is approximately 3:2.
- the resulting reaction products may serve as active ingredients in compositions suitable for contact with a subject.
- active ingredients may be combined with numerous ingredients to form products of numerous chemical applications, such as catalytical agents, crosslinking of polymers, superconducting electrical materials, pharmaceutical drugs, food supplements, etc.
- the active ingredients in suitable toxicological compositions can be applied to the skin, or other tissues of humans or other mammals.
- Such products may include a dermatologically or pharmaceutically acceptable carrier, vehicle or medium, for example, a carrier, vehicle or medium that is compatible with the tissues to which they will be applied.
- compositions in accordance with the present disclosure can contain any ingredient conventionally used in cosmetics and/or dermatology.
- active ingredients may be formulated to provide crystals in solution, as well as solid forms.
- products containing a reaction product in accordance with the present disclosure as an active ingredient can be in the form of solutions, emulsions (including microemulsions), suspensions, creams, lotions, gels, powders, or other typical solid or liquid compositions used for treatment of age related skin conditions.
- compositions may contain, in addition to the reaction product in accordance with this disclosure, other ingredients typically used in such products, such as antimicrobials, moisturizers and hydration agents, penetration agents, preservatives, emulsifiers, natural or synthetic oils, solvents, surfactants, detergents, gelling agents, emollients, antioxidants, fragrances, fillers, thickeners, waxes, odor absorbers, dyestuffs, coloring agents, powders, viscosity-controlling agents and water, and optionally including anesthetics, anti-itch actives, botanical extracts, conditioning agents, darkening or lightening agents, glitter, humectants, mica, minerals, polyphenols, silicones or derivatives thereof, sunblocks, vitamins, and phytomedicinals.
- other ingredients typically used in such products such as antimicrobials, moisturizers and hydration agents, penetration agents, preservatives, emulsifiers, natural or synthetic oils, solvents, surfactants, detergents, gelling
- products can be formulated to contain copper-zinc malonate in amounts from about 0.001 to about 5% by weight of the total composition.
- products can be formulated to contain copper-zinc malonate in an amount from about 0.05 to about 1.0% by weight of the total composition.
- the amount of copper-zinc malonate is from about 0.1 to about 0.5% by weight of the total composition.
- the copper-zinc malonate present may be in a pharmaceutically acceptable salt form.
- Other active ingredients may be provided in the formulations at the same concentrations.
- compositions in accordance with the present disclosure can be topically applied to skin in need of improvement such as the reduction or elimination of an undesirable dermatological condition.
- treat refers to using the actives or compositions of the present disclosure prophylactically to prevent outbreaks of undesirable dermatological conditions, or therapeutically to ameliorate an existing dermatological condition, and/or extend the duration of the aesthetic benefit of a skin procedure. A number of different treatments are now possible, which reduce and/or eliminate undesirable skin conditions.
- undesirable skin condition refers to any skin condition that may require treatment of any sort, including skin having one or more undesirable appearances and/or disagreeable tactile sensations.
- the term further refers to any cosmetically undesirable skin condition, as well as any undesirable diseased or damaged skin condition.
- Non-limiting examples of undesirable skin conditions which can be treated with the topical application of compositions in accordance with the present disclosure include: acne vulgaris (pimples); atopic dermatitis; birthmarks; cafe-au-laits spots; common benign skin tumors or growths; common diseases of the nail such as nail infections caused by bacteria, fungi, yeast and/or virus; paronychia; nail disorder due to skin disease such as psoriasis, and/or nail injury; common skin conditions around the eyes such as eyelid contact dermatitis, atopic dermatitis, bacterial skin infection (impetigo or conjunctivitis), xanthelasma, syringoma, skin tags, milia, Naevus, and/or portwine stains; common skin condition associated with housework such as irritant contact dermatitis, allergic contact dermatitis, contact urticaria, fungal infections, paronychia, and/or viral warts; common diseases of the scalp such as se
- compositions in accordance with the present disclosure are suitable for treating diseased skin, or any condition which can result from the excessive amount of pathogens such as fungi, viruses, and or bacterium affecting the skin in any way.
- an undesirable skin condition is skin that has a rough texture or uneven appearance such as psoriasis, bumps, razor burns, and/or patches.
- compositions generally depends on the purpose for which the composition is to be applied.
- dosage and frequency of application can vary depending upon the type and severity of the skin condition.
- Treatments in accordance with the present disclosure contact skin with one or more active ingredients such as those containing copper, zinc and/or silver in an effective amount to improve the undesirable skin conditions.
- patients are treated by topically applying to skin suffering a condition, one or more copper-zinc malonates.
- patients are treated by topically applying to skin suffering from a condition, one or more salts in accordance with the present disclosure.
- the active ingredient is applied until the treatment goals are obtained.
- the duration of the treatment can very depending on the severity of the condition. For example, treatments can last several weeks to months depending on whether the goal of treatment is to reduce or eliminate the skin condition.
- compositions and methods in accordance with the present disclosure can be combined with other skin treatment systems.
- the bimetallic salt complexes and be applied to skin in combination with skin treatment systems such as the Obagi NuDerm® skin treatment system and related Obagi skin care products from O.M.P. Inc. of Long Beach Calif.
- More specifically copper-zinc malonate compositions can be combined with the Obagi Nuderm® skin treatment system in order to promote the beneficial affects of that system.
- the active ingredients and formulations in accordance with the present disclosure may either be incorporated into other product formulations, or applied to the skin before, after, and/or during other skin treatments.
- compositions may contain any active ingredient or be formulated and applied as described in commonly owned U.S. Patent Application entitled Anti-aging Treatment Using Copper-Zinc Compositions (U.S. Ser. No. 11/452,642 filed Jun. 14, 2006) herein incorporated by reference in its entirety.
- Example 1 shows suitable ingredients of a reaction mixture for forming copper-zinc malonates in accordance with the present disclosure.
- copper-zinc malonate formulations have the following make-up:
- composition of example 5 suitable for treatment of skin containing an effective amount of copper-zinc malonate active ingredient is routinely applied to her face twice daily. Wrinkling is reduced or eliminated.
Abstract
Methods of forming bimetal complexes including reacting polyfunctional compounds with two or more coordination elements and recovering a bimetal complex.
Description
- This Application is a divisional application of U.S. application Ser. No. 11/668,020 filed Jan. 29, 2007 which is a continuation-in-part of U.S. application Ser. No. 11/647,623 filed Dec. 29, 2006, now U.S. Pat. No. 7,687,650 which claims priority benefit to U.S. Provisional Application No. 60/764,968 filed Feb. 3, 2006 the entire disclosures of which are incorporated herein by this reference.
- 1. Technical Field
- The present disclosure relates compositions that contain bimetal complexes. The bimetal complexes can be prepared by reacting a polyfunctional compound with two or more coordination elements.
- 2. Background of the Invention
- Polycarboxylic acids are polyfunctional acids used in many products. The ion form of carboxylic acids, as well as its esters and salts, are known as carboxylates. Various copper carboxylates are known through the extensive use of the carboxylate ion in crystal engineering to explore the structural chemistry of copper (II) carboxylates, which exist, for example as copper (II) malonates, copper (II) coppergiutamates, copper citrates and other copper complexes known.
- However, the study of copper (II) reaction products of polyfunctional acids and the formation of carboxylates are problematic in that the conditions of synthesis, stoichiometry and temperature should be known and applied in order to synthesize the desired product. For example, the mixture of copper carbonate and malonic acid in a 1:2 molar ratio kept at 5° C. for weeks results in the formation of deep blue copper (II) malonate trihydrate crystals.
- It would be desirable to provide compositions containing reaction products of polyfunctional carboxylic acid compounds with two or more coordination elements. For example, it would be desirable to provide malonates having both copper and at least one other metallic constituent, such as zinc. These can be obtained by reacting a mixture of malonic and a 3:1:1 molar ratio with the metallic components resulting in the formation of greenish-blue copper II zinc II malonate crystals.
- Polyamines are polyfunctional bases used in many products. When combined with metallic constituent, the ion form of amines as well as their amides and salts, can produce amino complexes. Various copper amine complexes are used extensively in crystal engineering to explore the structural chemistry of amine complexes, such as, for example, copper (II) amine complexes. Copper (II) amine complexes exist in numerous forms, many of which have an intense blue color. For example, intense blue various copper (II) ethylenediamine complexes are known.
- However, the study of reaction products of poly-functional amines and the formation of amine complexes are problematic in that conditions of synthesis, stoichiometry and temperature should be known and applied in order to synthesize the desired product. For example, a mixture of butylene diamine, copper chloride, zinc chloride in a 3:1:1 molar ratio results in the formation of dry, blue crystals.
- It would be desirable to provide compositions containing reactions products of polyfunctional amine compounds with two or more coordination elements. For example, it would be desirable to provide amines complexes having both copper and at least one other metallic constituent, such as zinc.
- Poly-functional organic compounds having a carboxyl group and an amine group are known as amino acids. The ionic form of amino acids vary with the pH of the media, with ionic forms of the acid being known as carboxylates and the ionic forms of the amine as being known as ammonium complexes.
- Various copper amino acid complexes are known through the extensive use of the amino acids in crystal engineering to explore the structural chemistry of copper (II) amino acid complexes. They exist in numerous forms such as copper (II) glycinate, copper II glutamate, etc. However, one study of reaction products of polyfunctional amino acids and the formation of amino acid complex is problematic in that conditions of synthesis, stoichiometry and temperature should be known and applied in order to synthesize the desired product.
- It would also be desirable to provide compositions containing reaction products of amino acid compounds with two or more coordination elements. For example, it would be also desirable to provide amino acid complexes having copper and at least one other metallic constituent, such as zinc. For example in a mixture of glutamic acid, zinc carbonate and copper carbonate in a 3:1:1 molar ratio results in the formation of greenish-blue crystals. It would be desirable to provide compositions containing reaction products of polyfunctional compounds with two or more coordination elements. It would also be desirable to provide glutamates having both copper and at least one other metallic constituent, such as zinc.
- Compositions in accordance with the present disclosure contain a bimetal complex. The bimetal complex can be the reaction product of a polyfunctional compound with two or more coordination elements. The polyfunctional compound can be, for example, a polyfunctional acid or an amino acid. The coordination elements can be selected from the elements listed in Groups IIIA to VIIIA, Groups IB to IIIB, of periods 4 and 5 and aluminum in Group IIIB, period 3 of The Periodic Table of the Elements.
- Methods of making such reaction products are also described. In embodiments, bimetal complexes are made by 1) contacting one or more polyfunctional compounds with two or more coordination elements, wherein the molar ratio of polyfunctional compound to two or more coordination elements is at least 3:2; and 2) isolating the reaction product.
- In embodiments, copper-zinc malonate complexes are synthesized from malonic acid and copper and zinc constituents. Methods of making copper-zinc dual salts are also described. In embodiments, copper-zinc malonate compositions are made by:
- 1) contacting malonic acid with one or more bases containing copper and zinc constituents in an aqueous solution, wherein the molar ratio of malonic acid to copper to zinc is about 3:1:1; and 2) recovering the copper-zinc malonate product.
- Excess malonic acid in the manufacturing process may drive the formation of copper-zinc malonates which precipitate in the reaction solution.
- The preparation of reaction products of polyfunctional compounds with two or more coordination elements and compositions containing such reaction products are described.
- The polyfunctional compound can be any compound that contains at least two functional groups that may complex with metal cations in solution. Among the functional groups that may be present include carboxylic acid groups and amino groups. Suitable polyfunctional compounds include, but are not limited to polyfunctional acids, polyfunctional amines and amino acids. Other suitable polyfunctional compounds will be readily envisioned by those skilled in the art reading the present disclosure. It should of course be understood that mixtures of polyfunctional compounds may be used.
- Polyfunctional acids are primarily monomeric compositions having two or more carboxylic acid groups. Non-limiting examples of polyfunctional acids include maleic acid, fumaric acid, citraconic acid, itaconic acid, glutaconic acid, phthalic acid, isophthalic acid, terephthalic acid, cyclohexane dicarboxylic acid, succinic acid, adipic acid, sebacic acid, azealic acid, malonic acid, dodecanedioic acid, 1,18-octadecanedioic acid, dimer acids (prepared from a mono-, di- or triunsaturated fatty acid, acid wax, acid anhydride grafted wax, or other suitable polycarboxylic acid reacting compound), alkenyl succinic acids (such as n-dodecenylsuccinic acid, docecylcucinic acid and octadecenylsuccinic acid). The polyfunctional acid can be present in acidic form, anhydride form, salt form, or mixtures thereof.
- Amino acids may also be used as the polyfunctional compound. Amino acids are known to those skilled in the art and include at least a carboxylic acid functionality and an amino functionality. Suitable amino acids include naturally occurring amino acids and synthetic amino acids. Non-limiting examples of amino acids include, but are not limited to: glycine; aminopolycarboxylic acids (e.g., aspartic acid, β-hydroxyaspartic acid, glutamic acid, β-hydroxyglutamic acid, β-methylaspartic acid, β-methylglutamic acid, β,β-dimethylaspartic acid, γ-hydroxyglutamic acid, β,γ-dihydroxyglutamic acid, β-phenylglutamic acid, γ-methyleneglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid); amino acid amides such as glutamine and asparagine; polyamino- or polybasic-monocarboxylic acids such as arginine, lysine, β-aminoalanine, γ-aminobutyrine, ornithine, citruline, homoarginine, homocitrulline, hydroxylysine, allohydroxylsine and diaminobutyric acid; other basic amino acid residues such as histidine; diaminodicarboxylic acids such as α,α′-diaminosuccinic acid, α,α′-diaminoglutaric acid, α,α′-diaminoadipic acid, α,α′-diaminopimelic acid, α,α′-diamino-β-hydroxypimelic acid, α,α′-diaminosuberic acid, α,α′-diaminoazelaic acid, and α,α′-diaminosebacic acid; imino acids such as proline, hydroxyproline, allohydroxyproline, γ-methylproline, pipecolic acid, 5-hydroxypipecolic acid, and azetidine-2-carboxylic acid; mono- or dialkyl (typically C1 -C8 branched or normal) amino acids such as alanine, valine, leucine, allylglycine, butyrine, norvaline, norleucine, heptyline, α-methylserine, α-amino-α-methyl-γ-hydroxyvaleric acid, α-amino-α-methyl-δ-hydroxyvaleric acid, α-amino-α-methyl-ε-hydroxycaproic acid, isovaline, α-methylglutamic acid, α-aminoisobutyric acid, α-aminodiethylacetic acid, α-aminodiisopropylacetic acid, α-aminodi-n-propylacetic acid, α-aminodiisobutylacetic acid, α-aminodi-n-butylacetic acid, α-aminoethylisopropylacetic acid, α-amino-n-propylacetic acid, aaminodiisoamyacetic acid, α-methylaspartic acid, α-methylglutamic acid, 1-aminocyclopropane-1-carboxylic acid, isoleucine, alloisoleucine, tert-leucine, β-methyltryptophan and α-amino-β-ethyl-β-phenylpropionic acid; β-phenylserinyl; aliphatic α-amino-β-hydroxy acids such as serine, β-hydroxyleucine, β-hydroxynorleucine, β-hydroxynorvaline, and α-amino-β-hydroxystearic acid; α-Amino, α-, γ-, δ- or ε-hydroxy acids such as homoserine, γ-hydroxynorvaline, δ-hydroxynorvaline and epsilon-hydroxynorleucine residues; canavine and canaline; γ-hydroxyornithine; 2.hexosaminic acids such as D-glucosaminic acid or D-galactosaminic acid; α-Amino-β-thiols such as penicillamine, β-thiolnorvaline or β-thiolbutyrine; other sulfur containing amino acid residues including cysteine; homocystine, β-phenylmethionine, methionine, S-allyl-L-cysteine sulfoxide, 2-thiolhistidine, cystathionine, and thiol ethers of cysteine or homocysteine; phenylalanine, tryptophan and ring-substituted α amino acids such as the phenyl- or cyclohexylamino acids α-aminophenylacetic acid, aaminocyclohexylacetic acid and α-amino-β-cyclohexylpropionic acid; phenylalanine analogues and derivatives comprising aryl, lower alkyl, hydroxy, guanidino, oxyalkylether, nitro, sulfur or halo-substituted phenyl (e.g., tyrosine, methyltyrosine and o-chloro-, p-chloro-, 3,4-dicloro, o-, m- or p-methyl-, 2,4,6-trimethyl-, 2-ethoxy-5-nitro-, 2-hydroxy-5-nitro- and p-nitrophenylalanine); furyl-, thienyl-, pyridyl-, pyrimidinyl-, purinyl- or naphthylalanines; and tryptophan analogues and derivatives including kynurenine, 3-hydroxykynurenine, 2-hydroxytryptophan and 4-carboxytryptophan; α-Amino substituted amino acids including sarcosine (N-methylglycine), N-benzylglycine, N-methylalanine, N-benzylalanine, N-methylphenylalanine, N-benzylphenylalanine, N-methylvaline and N-benzylvaline; and α-Hydroxy and substituted α-hydroxy amino acids including serine, threonine, allothreonine, phosphoserine and phosphothreonine. glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline. Aminopolycarboxylic acids, e.g., aspartic acid, β-hydroxyaspartic acid, glutamic acid, β-hydroxyglutamic acid, β-methylaspartic acid, β-methylglutamic acid, β,β-dimethylaspartic acid, γ-hydroxyglutamic acid, β,γ-dihydroxyglutamic acid, β-phenylglutamic acid, γ-methyleneglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid. Polyaminoacids may also be used provided they form complexes with the coordination elements employed.
- The polyfunctional compound is reacted with two or more coordination elements. The coordination elements can be chosen from the elements listed in Groups IIIA to VIIIA, Groups IB to IIIB, of periods 4 and 5 and aluminum in Group IIIB, period 3 of The Periodic Table of the Elements. Suitable non-limiting examples of elements listed in group IB of The Periodic Table of Elements include copper, silver, and gold. Suitable non-limiting examples of coordination elements include aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, and indium. Tin may also be used. Those skilled in the are will readily envision suitable compounds for providing the coordination elements in solution.
- For example, water soluble salts containing the coordination element may be used. The salts may be organic or inorganic. Suitable water-soluble silver salts include silver nitrate, silver acetate, silver propionate, silver sulfate, silver butyrate, silver isobutyrate, silver benzoate, silver tartrate, silver salicylate, silver malonate, silver succinate and silver lactate. Suitable water-soluble aluminum salts include aluminum potassium sulfate, aluminum chloride, aluminum sodium sulfate, aluminum sodium phosphate, aluminum sulfate, aluminum nitrate, and sodium aluminate. Suitable water-soluble copper salts include copper sulfate, fluoroborate, hydroxide, borate, fluoride, carbonate, oxychloride, formate or acetate. Suitable water-soluble zinc salts include zinc chloride, zinc bromide, zinc iodide, zinc chlorate, zinc bromate, zinc chlorite, zinc perchlorate, zinc sulfate, zinc nitrate, zinc nitrite, zinc borate, zinc metaborate, basic zinc borate, zinc hexafluorosilicate, zinc hypophosphite, zinc glycerophosphate, zinc bichromate, zinc citrate, zinc thionate, zinc dithionate, zinc tetrathionate, zinc pentathionate, zinc thiocyanate, zinc benzoate, zinc acetate, zinc salicylate, zinc picrate, zinc permanganate, zinc hydrogen phosphate, zinc formate, zinc ethylsulfate and zinc phenolsulfonate. Examples of suitable water soluble nickel salts that may be used include nickel sulfate hexahydrate and nickel chloride hexahydrate. It should be understood that the listed salts are only a small portion of the salts suitable for use in accordance with the present disclosure. For example, inorganic salts are suitable provided that they provide coordination element cations when placed in an aqueous solution. Thus, the foregoing list of salts should be considered a non-limiting, illustrative list.
- For carrying out the process, a reaction solution can be prepared by mixing the various ingredients in water. Water in the mixture may advantageously be added in limited amounts sufficient to allow the reaction product to precipitate from solution upon formation. Accordingly, the reaction mixture is not so dilute as to prevent product precipitate formation. Where necessary, mixing and heating can be used to bring the reactants to 40-100° C. in order to solubilize the reactants. As a result, reactant solubility may be enhanced through energy input such as microwave heating or addition of boiling water. The input of the energy may take place through any instrument capable of heating the aqueous reaction mixture. The reaction products formed in solution may be immediately separated so that their production can take place in a continuous process. Where a short reaction time and rapid crystallization of the reaction product occur, the conversion may be carried out continuously, and the recovery of the resultant solid product may take place by any conventional manner such as filtering, centrifugation, or sedimentation.
- The polyfunctional compound is present in the reaction mixture in amounts that will contact metal cations in an aqueous solution. Suitable amounts of polyfunctional compound also include excess amounts in relation to the amount of metal cations. In embodiments, polyfunctional compound is present in a 3:1:1 molar ratio in relation to the metal constituents. In embodiments, the polyfunctional compound is malonic acid which can be present in acidic form, salt form, or mixtures thereof. In embodiments, the process parameters are especially advantageous if the polyfunctional compound is added to excess in comparison to the metal counter cation constituents. Depending on the desired complex, the latter are added so that the molar ratio of polyfunctional compound to metal ions is approximately 3:2.
- In embodiments, the coordination elements may be present as one or more ionic compounds formed by joining one or more independent coordination element molecules or ions of a first type and coordination element molecules or ions of a second type to a central unit by ionic bonds. For example, the reaction product may be in the form of a trinuclear cation, where structurally independent coordination element hydrates are bridged by a central unit. However, various coordination modes are possible depending on the source of the coordination elements and synthesis conditions. In embodiments, the central unit may be a multi-membered ring such as eight-membered ring, six-membered ring, and four-membered metalocycle for bridging or chelating functions between the coordination element constituents. Accordingly, the crystal structures of the reaction products can be very diverse, from ionic to three-dimensional polymers. In embodiments, the reaction products are present in several hydrate, and polymorphic forms.
- In embodiments, suitable reaction products can be non-toxic bimetal complexes that include copper, zinc, aluminum and/or silver constituents. Such copper, zinc, aluminum and/or silver reaction products include, but are not limited to water soluble compounds that contain copper, zinc, aluminum and/or silver. Non-limiting examples of water-soluble bimetal complexes include copper-zinc citrate, copper-silver citrate, silver-zinc citrate, copper-zinc oxalate, copper-silver oxalate, silver-zinc oxalate, copper-zinc tartarate, copper-silver tartarate, silver-zinc tartarate, copper-zinc malate, copper-silver malate, silver-zinc malate, copper-zinc succinate, copper-silver succinate, silver-zinc succinate, copper-zinc malonate, copper-silver malonate, silver-zinc malonate, copper-zinc maleate, copper-silver maleate, silver-zinc maleate, copper-zinc aspartate, copper-silver aspartate, silver-zinc aspartate, copper-zinc glutamate, copper-silver glutamate, silver-zinc glutamate, copper-zinc glutarate, copper-silver glutarate, silver-zinc glutarate, copper-zinc fumarate, copper-silver fumarate, silver-zinc fumarate, copper-zinc glucarate, copper-silver glucarate, silver-zinc glucarate, copper-zinc polyacrylic acid, copper-silver polyacrylic acid, silver-zinc polyacrylic acid, and combinations thereof. In embodiments, copper, zinc, aluminum and silver salts of organic multi carboxylic acids are suitable for use in accordance with the present disclosure. In embodiments, suitable salts can be doped such that the unit cell of the salt has zinc or silver constituents dispersed therein. Such zinc or silver constituents may either substitute another metallic constituent or fill a preexisting void in the unit cell.
- In embodiments, suitable reaction products can be copper salts having zinc or silver constituents therein. For example, zinc or silver may either substitute a copper constituent or fill a preexisting void in the copper salt's unit cell. Suitable non-limiting examples of copper salts which may be used to form bimetallic complexes include copper (II) malonate and any hydrated form thereof such as copper (II) malonate dihydrate, copper (II) malonate trihydrate, and copper malonate tetrahydrate. Other suitable non-limiting examples of suitable copper salt active ingredients include copper citrate, copper oxalate, copper tartarate, copper malate, copper succinate, copper malonate, copper maleate, copper aspartate, copper glutamate, copper glutarate, copper fumarate, copper glucarate, copper polyacrylic acid, and combinations thereof. In embodiments, suitable copper salts can be doped such that the unit cell of the salt has zinc or silver constituents dispersed therein. Such zinc or silver constituents may either substitute a copper constituent or fill a preexisting void in the unit cell.
- In embodiments, malonic acid may be reacted with salts containing copper and zinc constituents in an aqueous solution. It has been found that where the malonic acid, copper and zinc constituents are present in at least about a 3:1:1 molar ratio, copper-zinc malonates may be produced in good yield and high crystalline purity.
- Malonic acid refers to 1,3-propanedioic acid, a dicarboxylic acid with structure CH2(COOH)2 or:
- The ion form of malonic acid, as well as its esters and salts, are known as malonates. For example, diethyl malonate is ethyl ester of malonic acid. As used herein, the term copper-zinc malonate applies to any salt substances formed from malonic acid having copper and zinc constituents.
- Suitable ingredients for the formation of copper-zinc malonates include malonic acid, one or more bases of copper and zinc, and water. In an aqueous reaction solution, suitable salt forms provide copper and zinc cations capable of bonding to malonate anions. Other suitable ingredients for the formation of copper-zinc malonates will include the replacement of bases of copper and zinc with the metallic form of copper and zinc. The elemental form of copper and zinc are known as copper and zinc metals and will be dissolved in the acidic water media as they react with malonic acid.
- One or more salts containing copper and zinc constituents are present in amounts that will contact malonic acid in an aqueous solution. Suitable salts for making copper-zinc malonate compositions in accordance with this disclosure include metal salts containing complex-forming metal ions of copper and/or zinc. Non-limiting examples of suitable metal salts are copper (I) and (II) salts such as copper chloride, copper bromide, copper fluoride, copper nitrate, copper fluoroborate, copper sulfate, copper acetate, copper trifluoro acetate, copper stearate, copper octoate, copper methacrylate, copper malonate, copper benzoate; zinc salts such as zinc bromide, zinc chromate, zinc chloride, zinc stearate, zinc octoate, and zinc ethylhexoate. In embodiments, the aqueous solution may include one or more metallic salts, such as cupric carbonate (CuCO3.Cu(OH)2), zinc carbonate (3Zn(OH)2.2ZnCO3), metallic copper, metallic zinc and combinations thereof. Basic salts such as basic zinc salts, basic copper salts, and combinations thereof are also suitable for use in accordance with the present disclosure. In embodiments, suitable metal basic salts are: copper (I) and (II) salts such as copper carbonate, copper oxide, and copper hydroxide; and zinc salts such as zinc carbonate, zinc oxide, and zinc hydroxide.
- It should be understood that the listed salts are only a small portion of the salts suitable for use in accordance with the present disclosure. For example, inorganic salts are suitable provided that they provide copper and zinc cations when placed in an aqueous solution. Thus, the foregoing list of salts should be considered a non-limiting, illustrative list.
- For carrying out the process, the reaction solution can be prepared by mixing the various ingredients in water where malonic acid and the salts may ionize and become more reactive. Water in the mixture is added in limited amounts sufficient to allow copper-zinc malonates to precipitate from solution upon formation. Accordingly, the reaction mixture is not so dilute as to prevent product precipitate formation. Where copper and zinc salts in the reaction mixture are insoluble and form dispersions (such as at cooler temperatures), mixing and heating steps can be applied to bring the reactants to 40-100° C. in order to solubilize the reactants. As a result, reactant solubility may be enhanced through energy input such as microwave heating or addition of boiling water dissolver. The input of the energy may take place through any instrument capable of heating the aqueous reaction mixture. The copper-zinc malonate complexes formed in solution may be immediately separated so that their production can take place in a continuous process. Due to the short reaction time and the rapid crystallization of the copper-zinc malonate product, the conversion may be carried out continuously, and the recovery of the resultant solid product may take place by any conventional manner such as filtering, centrifugation, or sedimentation.
- In the production of the reaction mixture, the concentration of the polyfunctional compound and that of the copper and zinc constituents may be pre-selected so that the total concentration of product formed exceeds the solubility equilibrium. This will result in product precipitating from solution in solid form for easy collection.
- In embodiments, the final composition may be a deep blue crystal having good yield and substantial crystalline purity. Suitable copper-zinc malonate forms in accordance with the present disclosure include any salt formed from the neutralization of malonic acid by one or more copper containing molecules and one or more zinc containing molecules. Illustrative examples include salt formed by the neutralization of malonic acid by cupric carbonate (CuCO3.Cu(OH)2), and zinc carbonate (3Zn(OH)2.2ZnCO3) in an aqueous solution. Here copper may be added first, followed by zinc in order to obtain the salts of the present disclosure.
- In embodiments, the copper-zinc malonates may be one or more ionic compounds formed by joining one or more independent copper molecules or ions and one or more independent zinc molecules or ions to a central unit by ionic bonds. For example, the copper-zinc malonate may be in the form of a trinuclear cation, where structurally independent copper and zinc hydrates are bridged by a central unit such as an octahedral diaquadimalonatocopper (II) unit. However, various coordination modes are possible depending on the source of the copper and zinc and synthesis conditions. In embodiments, the central unit malonate ion may be a multi-membered ring such as eight-membered ring, six-membered ring, and four-membered metalocycle for bridging or chelating functions between the copper and zinc constituents. Accordingly, the crystal structures of copper-zinc malonates can be very diverse, from ionic to three-dimensional polymers. In embodiments, the copper-zinc malonates can be found in several hydrate, and polymorphic forms.
- In embodiments, the process parameters are especially advantageous if the polyfunctional compound is added to excess in comparison to the metal counter cation constituents. Depending on the desired complex, the latter are added so that the molar ratio of polyfunctional compound to metal ions is approximately 3:2.
- In embodiments, the resulting reaction products may serve as active ingredients in compositions suitable for contact with a subject. Such active ingredients may be combined with numerous ingredients to form products of numerous chemical applications, such as catalytical agents, crosslinking of polymers, superconducting electrical materials, pharmaceutical drugs, food supplements, etc. The active ingredients in suitable toxicological compositions can be applied to the skin, or other tissues of humans or other mammals. Such products may include a dermatologically or pharmaceutically acceptable carrier, vehicle or medium, for example, a carrier, vehicle or medium that is compatible with the tissues to which they will be applied. The term “dermatologically or pharmaceutically acceptable,” as used herein, means that the compositions or components thereof so described are suitable for use in contact with these tissues or for use in patients in general without undue toxicity, incompatibility, instability, allergic response, and the like. In embodiments, compositions in accordance with the present disclosure can contain any ingredient conventionally used in cosmetics and/or dermatology. In embodiments, active ingredients may be formulated to provide crystals in solution, as well as solid forms.
- In embodiments, products containing a reaction product in accordance with the present disclosure as an active ingredient can be in the form of solutions, emulsions (including microemulsions), suspensions, creams, lotions, gels, powders, or other typical solid or liquid compositions used for treatment of age related skin conditions. Such compositions may contain, in addition to the reaction product in accordance with this disclosure, other ingredients typically used in such products, such as antimicrobials, moisturizers and hydration agents, penetration agents, preservatives, emulsifiers, natural or synthetic oils, solvents, surfactants, detergents, gelling agents, emollients, antioxidants, fragrances, fillers, thickeners, waxes, odor absorbers, dyestuffs, coloring agents, powders, viscosity-controlling agents and water, and optionally including anesthetics, anti-itch actives, botanical extracts, conditioning agents, darkening or lightening agents, glitter, humectants, mica, minerals, polyphenols, silicones or derivatives thereof, sunblocks, vitamins, and phytomedicinals.
- As an illustrative example, products can be formulated to contain copper-zinc malonate in amounts from about 0.001 to about 5% by weight of the total composition. In embodiments, products can be formulated to contain copper-zinc malonate in an amount from about 0.05 to about 1.0% by weight of the total composition. In other embodiments, the amount of copper-zinc malonate is from about 0.1 to about 0.5% by weight of the total composition. Here, the copper-zinc malonate present may be in a pharmaceutically acceptable salt form. Other active ingredients may be provided in the formulations at the same concentrations.
- In embodiments, compositions in accordance with the present disclosure can be topically applied to skin in need of improvement such as the reduction or elimination of an undesirable dermatological condition. As used herein the word “treat,” “treating” or “treatment” refers to using the actives or compositions of the present disclosure prophylactically to prevent outbreaks of undesirable dermatological conditions, or therapeutically to ameliorate an existing dermatological condition, and/or extend the duration of the aesthetic benefit of a skin procedure. A number of different treatments are now possible, which reduce and/or eliminate undesirable skin conditions.
- As used herein “undesirable skin condition” refers to any skin condition that may require treatment of any sort, including skin having one or more undesirable appearances and/or disagreeable tactile sensations. The term further refers to any cosmetically undesirable skin condition, as well as any undesirable diseased or damaged skin condition.
- Non-limiting examples of undesirable skin conditions which can be treated with the topical application of compositions in accordance with the present disclosure include: acne vulgaris (pimples); atopic dermatitis; birthmarks; cafe-au-laits spots; common benign skin tumors or growths; common diseases of the nail such as nail infections caused by bacteria, fungi, yeast and/or virus; paronychia; nail disorder due to skin disease such as psoriasis, and/or nail injury; common skin conditions around the eyes such as eyelid contact dermatitis, atopic dermatitis, bacterial skin infection (impetigo or conjunctivitis), xanthelasma, syringoma, skin tags, milia, Naevus, and/or portwine stains; common skin condition associated with housework such as irritant contact dermatitis, allergic contact dermatitis, contact urticaria, fungal infections, paronychia, and/or viral warts; common diseases of the scalp such as seborrhoeic dermatitis, psoriasis of the scalp, lichen planus, discoid lupus erythematosus (DLE), alopecia areata, seborrhoeic keratoses (seborrhoeic warts, age spots), solar keratoses, angiosarcoma, fungal infection (ringworm, tinea Capitis), bacteria infections of the hair follicles (folliculitis, boils), and/or shingles (Herpes Zoster); common diseases in children such as atopic dermatitis, atopic eczema, discoid eczema, pityriasis alba, vitiligo, and/or alopecia areata; common diseases of the mouth and lips such as oral candidiasis, oral leukoplakia, apthous ulcers, and/or oral lichen planus; common skin problems in elderly such as appearance and texture changes, senile purpura, xerosis/asteatotic eczema, skin Infections/infestations, pigmentary changes, blistering disorders, non-cancerous skin growths, cancerous skin growths, adverse drug reaction, and/or stasis dermatitis; common viral warts; contact allergy; diaper candidiasis, drug allergy, folliculitis; freckles; fungal infections of the skin such as white spot, athlete's foot, jock itch, and/or moniliasis/candidiasis; guttate hypomelanosis; hair loss; hand eczema; impetigo; lines, crow's feet, wrinkles, etc.; melasma; molluscum contagiosum; occupational skin disease such as irritation and/or allergy; post-Inflammatory pigmentation; psoriasis; rosacea; shingles; skin cancers; skin diseases in diabetes mellitus; skin diseases in pregnancy; skin disorders caused by cosmetics such as irritant contact dermatitis and/or allergic contact dermatitis, cosmetic induced pimples (acne), sunscreens allergy, and/or special cosmetic allergies, solar lentigenes; tinea capitis; viral warts; vitiligo; and combinations of these undesirable skin conditions.
- In embodiments, compositions in accordance with the present disclosure are suitable for treating diseased skin, or any condition which can result from the excessive amount of pathogens such as fungi, viruses, and or bacterium affecting the skin in any way.
- In embodiments, an undesirable skin condition is skin that has a rough texture or uneven appearance such as psoriasis, bumps, razor burns, and/or patches.
- The particular active ingredient or ingredients employed, and the concentration in the compositions, generally depends on the purpose for which the composition is to be applied. For example, the dosage and frequency of application can vary depending upon the type and severity of the skin condition.
- Treatments in accordance with the present disclosure contact skin with one or more active ingredients such as those containing copper, zinc and/or silver in an effective amount to improve the undesirable skin conditions. In embodiments, patients are treated by topically applying to skin suffering a condition, one or more copper-zinc malonates. In embodiments, patients are treated by topically applying to skin suffering from a condition, one or more salts in accordance with the present disclosure. The active ingredient is applied until the treatment goals are obtained. However, the duration of the treatment can very depending on the severity of the condition. For example, treatments can last several weeks to months depending on whether the goal of treatment is to reduce or eliminate the skin condition.
- In treatment embodiments, the compositions and methods in accordance with the present disclosure can be combined with other skin treatment systems. For example, the bimetallic salt complexes and be applied to skin in combination with skin treatment systems such as the Obagi NuDerm® skin treatment system and related Obagi skin care products from O.M.P. Inc. of Long Beach Calif. More specifically copper-zinc malonate compositions can be combined with the Obagi Nuderm® skin treatment system in order to promote the beneficial affects of that system. The active ingredients and formulations in accordance with the present disclosure may either be incorporated into other product formulations, or applied to the skin before, after, and/or during other skin treatments.
- In embodiments, the compositions may contain any active ingredient or be formulated and applied as described in commonly owned U.S. Patent Application entitled Anti-aging Treatment Using Copper-Zinc Compositions (U.S. Ser. No. 11/452,642 filed Jun. 14, 2006) herein incorporated by reference in its entirety.
- The following non-limiting examples further illustrate compositions and methods in accordance with this disclosure.
- Example 1 below shows suitable ingredients of a reaction mixture for forming copper-zinc malonates in accordance with the present disclosure.
-
Ingredient Amount Malonic acid 1.8 g cupric carbonate 0.632 g zinc carbonate 0.626 g Water 100 ml - 1.8 g of malonic acid (CH2(COOH)2) was combined with 0.632 grams of cupric carbonate (CuCO3.Cu(OH)2), 0.626 g of zinc carbonate (3Zn(OH)2.2ZnCO3) , and 100 ml of water to form a dispersion. The solution was heated until the reactants went into solution. Well-defined deep-blue crystals precipitated and were separated from the aqueous solution of malonic acid, cupric carbonate, and zinc carbonate (3:1:1 molar ratio) that had been kept at room temperature. Dual salt was formed by replacing acid groups with copper and zinc cations in the same molecule. The deep blue crystals were found to have a melting point of about 210° C.
- Sample prepared as per ASTM-D-1971-95 (herein incorporated by reference in its entirety) and analyzed by method 6010 (I.C.P.) (herein incorporated by reference in its entirety) showed 16.5% copper and 12.4% zinc.
- 1.8 g of malonic acid (CH2(COOH)2) was combined with 0.632 grams of cupric carbonate (CuCO3.Cu(OH)2), 0.626 g of zinc carbonate (3Zn(OH)2.2ZnCO3) , and 100 ml of boiling water. Well-defined deep-blue crystals were separated from the aqueous solution of malonic acid, cupric carbonate, and zinc carbonate (3:1:1 molar ratio) that had been kept at room temperature for 1 week.
- 3 moles of malonic acid is thoroughly mixed with 1 mole of copper as cupric carbonate and 1 mole of zinc as zinc carbonate in a stirred tank reactor containing 100 ml of heated water (approximately 95-100° C.). After a short reaction time, copper-zinc malonate precipitates out of solution with a high yield. A filtration step is used to isolate the complex as a powder. Deep blue crystals are obtained having a melting point of about 210° C.
- In embodiments, copper-zinc malonate formulations have the following make-up:
-
COMPONENT % BY WEIGHT Copper-zinc malonate* 0.1% (Active ingredient) Glycerine 3.0% Propylene Glycol 25.0% Distilled Water 71.9% - A 72 year old woman is suffering from wrinkling on her face. The composition of example 5 suitable for treatment of skin containing an effective amount of copper-zinc malonate active ingredient is routinely applied to her face twice daily. Wrinkling is reduced or eliminated.
- 3 moles of glutamic acid is thoroughly mixed with 1 mole of copper as cupric carbonate and 1 mole of zinc as zinc carbonate in a stirred tank reactor containing 100 ml of heated water (approximately 95-100° C.). After a short reaction time, copper-zinc glutamate precipitates out of solution with a high yield. A filtration step is used to isolate the complex as a powder.
- While several embodiments of the disclosure have been described, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
Claims (11)
1. A method of forming a bimetal complex comprising
dissolving an amino acid having at least two carboxylic acid groups in a solvent to form a solution;
adding a source of a first coordination element to the solution;
adding a source of a second coordination element to the solution,
wherein the first coordination element is different from the second coordination element and the first and second coordination elements are individually selected from copper, silver, gold, aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, indium and tin; and
recovering a bimetal complex.
2. A method as in claim 1 wherein the coordination first and second elements are copper and zinc, respectively.
3. A method as in claim 1 wherein the source of a first coordination element provides Cu+2 ions in the solution.
4. A method as in claim 1 wherein the source of a second coordination element provides Zn+2 ions in the solution.
5. A method as in claim 1 wherein the source of a first coordination element and the source of a second coordination element provides, respectively, are compounds of the formula Cu(O2C—CH2CO2)2 and Zn(O2C—CH2CO2)2.
6. A method as in claim 1 wherein the amino acid having at least two carboxylic acid groups is a glutamic acid or an aspartic acid.
7. A method of forming a bimetal complex comprising
dissolving a polyamine in a solvent to form a solution;
adding a source of a first coordination element to the solution;
adding a source of a second coordination element to the solution,
wherein the first coordination element is different from the second coordination element and the first and second coordination elements are individually selected from copper, silver, gold, aluminum, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, gallium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, silver, cadmium, indium and tin; and
recovering a bimetal complex.
8. A method as in claim 7 wherein the coordination first and second elements are copper and zinc, respectively.
9. A method as in claim 7 wherein the source of a first coordination element provides Cu+2 ions in the solution.
10. A method as in claim 7 wherein the source of a second coordination element provides Zn+2 ions in the solution.
11. A method as in claim 7 wherein the source of a first coordination element and the source of a second coordination element provides, respectively, are compounds of the formula Cu(O2C—CH2CO2)2 and Zn(O2C—CH2CO2)2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/011,144 US20110178318A1 (en) | 2006-02-03 | 2011-01-21 | Methods of making bimetal complexes |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76496806P | 2006-02-03 | 2006-02-03 | |
US11/647,623 US7687650B2 (en) | 2006-02-03 | 2006-12-29 | Chemical compositions and methods of making them |
US11/668,020 US7897800B2 (en) | 2006-02-03 | 2007-01-29 | Chemical compositions and methods of making them |
US13/011,144 US20110178318A1 (en) | 2006-02-03 | 2011-01-21 | Methods of making bimetal complexes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/668,020 Division US7897800B2 (en) | 2006-02-03 | 2007-01-29 | Chemical compositions and methods of making them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110178318A1 true US20110178318A1 (en) | 2011-07-21 |
Family
ID=38006571
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/668,020 Active US7897800B2 (en) | 2006-02-03 | 2007-01-29 | Chemical compositions and methods of making them |
US13/011,144 Abandoned US20110178318A1 (en) | 2006-02-03 | 2011-01-21 | Methods of making bimetal complexes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/668,020 Active US7897800B2 (en) | 2006-02-03 | 2007-01-29 | Chemical compositions and methods of making them |
Country Status (8)
Country | Link |
---|---|
US (2) | US7897800B2 (en) |
EP (1) | EP1816116B3 (en) |
JP (2) | JP5469797B2 (en) |
KR (1) | KR101509239B1 (en) |
CA (1) | CA2576640C (en) |
ES (1) | ES2456142T7 (en) |
MX (1) | MX2007001296A (en) |
PL (1) | PL1816116T6 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012174076A1 (en) * | 2011-06-13 | 2012-12-20 | Jr Chem, Llc | Appliances and compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008007868A1 (en) * | 2006-07-13 | 2008-01-17 | Mazence Inc. | Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
GB0413092D0 (en) * | 2004-06-11 | 2004-07-14 | Degussa | Process for preparing amino acids using the amidocarbonylation reaction (1) |
GB0413090D0 (en) * | 2004-06-11 | 2004-07-14 | Degussa | Process for preparing amino acids using the amidocarbonylation reaction (2) |
US7897800B2 (en) * | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7687650B2 (en) * | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US8273791B2 (en) * | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
WO2010085753A1 (en) * | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
US20110008271A1 (en) | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US20120315223A1 (en) * | 2011-06-13 | 2012-12-13 | Ramirez Jose E | Compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions |
US20120315224A1 (en) * | 2011-06-13 | 2012-12-13 | Ramirez Jose E | Appliances and compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions |
CA2890946C (en) | 2012-12-14 | 2020-06-09 | Hill's Pet Nutrition, Inc. | Anti-aging foods for companion animals |
Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US46494A (en) * | 1865-02-21 | Improved eye-water | ||
US51868A (en) * | 1866-01-02 | Improved remedy for sore eyes | ||
US87343A (en) * | 1869-03-02 | Improved medical compound | ||
US124751A (en) * | 1872-03-19 | Improvement in medical compounds or salves | ||
US171875A (en) * | 1876-01-04 | Improvement in cattle-washes | ||
US173607A (en) * | 1876-02-15 | Improvement in deodorizing, disinfecting, and antiseptic powders | ||
US1086900A (en) * | 1913-02-28 | 1914-02-10 | Kalil David | Remedy for syphilis. |
US1332190A (en) * | 1918-06-21 | 1920-02-24 | Meda Mfg Company | Cosmetic |
US1947568A (en) * | 1930-09-27 | 1934-02-20 | Drug Products Co Inc | Carron oil compound chlorinated cream |
US1949797A (en) * | 1929-07-30 | 1934-03-06 | Kaufmann Hans | Process of producing compositions of matter containing sulphur in colloidal distribution |
US2194218A (en) * | 1936-09-21 | 1940-03-19 | Dickeson Thurstan Wyatt | Stable emulsions of water with liquid or liquefiable substances which are immiscible with water |
US2344830A (en) * | 1940-08-15 | 1944-03-21 | Wisconsin Alumni Res Found | Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal |
US2370561A (en) * | 1941-07-11 | 1945-02-27 | Schuylkill Chemical Co | Therapeutic product and method of making same |
US2673364A (en) * | 1948-05-04 | 1954-03-30 | Twix Inc | Dental cleaning pad |
US2703777A (en) * | 1950-05-02 | 1955-03-08 | Iso Sol Company Inc | Ophthalmological preparations and vehicles and method of making the same |
US2736681A (en) * | 1955-02-11 | 1956-02-28 | Merck & Co Inc | Chemical compounds |
US2870151A (en) * | 1959-01-20 | Mqrpholine -ethers | ||
US2870150A (en) * | 1954-11-29 | 1959-01-20 | Abbott Lab | Morpholine ethers |
US2872372A (en) * | 1956-06-08 | 1959-02-03 | Ici Ltd | New indole derivatives |
US3164523A (en) * | 1961-03-22 | 1965-01-05 | Warner Lambert Pharmaceutical | Composition for skin beautification and treatment |
US3366114A (en) * | 1964-06-29 | 1968-01-30 | Saul L. Kanter | Ileostomy appliance |
US4138477A (en) * | 1976-05-28 | 1979-02-06 | Colgate Palmolive Company | Composition to control mouth odor |
US4146607A (en) * | 1977-11-07 | 1979-03-27 | Lever Brothers Company | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc |
US4255418A (en) * | 1979-05-14 | 1981-03-10 | Bailey Florence H | Anti-acne lotion |
US4309989A (en) * | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
US4310516A (en) * | 1980-02-01 | 1982-01-12 | Block Drug Company Inc. | Cosmetic and pharmaceutical vehicle thickened with solid emulsifier |
US4315916A (en) * | 1978-07-18 | 1982-02-16 | Lucille L. Filson | Topical salve |
US4322400A (en) * | 1978-12-19 | 1982-03-30 | Dragoco Inc. | Cosmetic stick composition |
US4372296A (en) * | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
US4376115A (en) * | 1980-08-05 | 1983-03-08 | Mccrorey Howard S | Method and composition for treating teeth and method for preparing same |
US4375968A (en) * | 1981-07-10 | 1983-03-08 | Manhart Mark J | Therapeutic calcium hydroxide dental preparation and method |
US4428933A (en) * | 1982-08-02 | 1984-01-31 | King John R | Composition for treating acne, method of manufacturing said composition, and method of treating skin |
US4430324A (en) * | 1981-11-27 | 1984-02-07 | Lever Brothers Company | Ammonium fluorometallate containing compositions |
US4503037A (en) * | 1981-03-17 | 1985-03-05 | Human Oltoanyagtermel/o/ es Kutato Intezet | Composition for the treatment of epithelial injuries and process for the preparation thereof |
US4568540A (en) * | 1984-04-18 | 1986-02-04 | Johnson & Johnson | Oral hygiene compositions |
US4647452A (en) * | 1985-11-08 | 1987-03-03 | Lever Brothers Company | Oral compositions of salicylamides and zinc salts for the synergistic inhibition of dental plaque |
US4652444A (en) * | 1984-12-14 | 1987-03-24 | National Research Laboratories | Methods and compositions for treating dental structures |
US4654213A (en) * | 1985-09-11 | 1987-03-31 | Cheesebrough-Pond's Inc. | Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt |
US4810693A (en) * | 1985-02-08 | 1989-03-07 | Procyte Corporation | Method for inducing biological coverings in wounds |
US4816254A (en) * | 1987-07-29 | 1989-03-28 | Moss Thomas D | Ointment for treating skin irritations |
US4816693A (en) * | 1987-08-21 | 1989-03-28 | National Electrostatics Corp. | Apparatus and method for uniform ion dose control |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US4992259A (en) * | 1990-01-03 | 1991-02-12 | Johnson & Johnson Consumer Products, Inc. | Stable oral composition of zinc |
US5079010A (en) * | 1988-09-22 | 1992-01-07 | Siegfreid Natterer | Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091193A (en) * | 1989-08-23 | 1992-02-25 | Roussel Uclaf | Diaper rash treatment and compositions |
US5177061A (en) * | 1985-02-08 | 1993-01-05 | Procyte Corporation | Method for stimulating hair growth using GHL-Cu complexes |
US5382431A (en) * | 1992-09-29 | 1995-01-17 | Skin Biology, Inc. | Tissue protective and regenerative compositions |
US5385727A (en) * | 1993-05-19 | 1995-01-31 | Church & Dwight Co., Inc. | Dentifrices containing zinc oxide particles and sodium bicarbonate |
US5480975A (en) * | 1994-02-08 | 1996-01-02 | Brigham And Women's Hospital | Induction of vascular endothelial growth factor (VEGF) by transition metals |
US5482720A (en) * | 1994-10-11 | 1996-01-09 | Church & Dwight Co., Inc. | Encapsulated co-micronized bicarbonate salt compositions |
US5484597A (en) * | 1993-07-30 | 1996-01-16 | Chesebrough-Pond's Usa Co. | Clear hydroalcholic cosmetic microemulsions |
US5597550A (en) * | 1994-12-09 | 1997-01-28 | Buxing Mo | Apparatus and method for administering minerals |
US5597552A (en) * | 1991-12-20 | 1997-01-28 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5708023A (en) * | 1994-03-28 | 1998-01-13 | The Trustees Of Columbia University In The City Of New York | Zinc gluconate gel compositions |
US5855873A (en) * | 1997-10-27 | 1999-01-05 | Church Dwight & Co., Inc. | Stable solution of zinc and bicarbonate ions |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US5858993A (en) * | 1994-03-28 | 1999-01-12 | Skin Biology, Inc. | Starch-metal complexes for skin and hair |
US5858335A (en) * | 1997-06-09 | 1999-01-12 | The Procter & Gamble Company | Method of reducing body odor using perfume-free two phase compositions |
US5861144A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Perfumed compositions for reducing body odors and excess moisture |
US5861147A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume |
US5861145A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method of reducing body odor using perfumed, odor absorbing, two phase compositions |
US5861143A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Methods for reducing body odors and excess moisture |
US5861146A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method for reducing body odor |
US5871719A (en) * | 1997-06-09 | 1999-02-16 | The Procter & Gamble Company | Perfume-free two phase compositions for reducing body odor |
US5871718A (en) * | 1997-06-09 | 1999-02-16 | The Procter & Gamble Company | Perfumed two phase compositions for reducing body odor |
US5874070A (en) * | 1997-06-09 | 1999-02-23 | The Procter & Gamble Company | Compositions for reducing body odor |
US5874067A (en) * | 1996-10-24 | 1999-02-23 | The Procter & Gamble Company | Methods for controlling environmental odors on the body |
US6019976A (en) * | 1997-03-26 | 2000-02-01 | Bryant; Andrew Edward | Formulations for treating male pattern baldness containing Serenoa repens, Vitamin B6, Vitamin B3, zinc and L-Arginine |
US6022565A (en) * | 1997-12-11 | 2000-02-08 | Albros, L.P. | Rhus dermatitis treatment composition and method |
US6030605A (en) * | 1997-04-03 | 2000-02-29 | Nabisco, Inc. | Breath freshening compositions and methods using them |
US6183785B1 (en) * | 1998-11-12 | 2001-02-06 | Geoffrey J. Westfall | Teat disinfectant |
US6191167B1 (en) * | 1997-12-29 | 2001-02-20 | Tristrata Technology, Inc. | Pharmaceutical compositions containing hydroxycarboxylic acid and/or ketocarboxylic acids and methods of using the same |
US6190407B1 (en) * | 1997-11-20 | 2001-02-20 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
US20020001629A1 (en) * | 2000-03-23 | 2002-01-03 | Voellmy Richard W. | Compositions and methods relating to prevention of chemotherapy-induced alopecia |
US20030004564A1 (en) * | 2001-04-20 | 2003-01-02 | Elkins Christopher J. | Drug delivery platform |
US20030026848A1 (en) * | 2001-07-06 | 2003-02-06 | Joshi Ashok V. | Beneficial materials for topical or internal use by a human or other animal |
US6518240B1 (en) * | 2000-10-11 | 2003-02-11 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes |
US6517849B1 (en) * | 1999-10-19 | 2003-02-11 | The Procter & Gamble Company | Tissue products containing antiviral agents which are mild to the skin |
US6521265B1 (en) * | 2000-02-09 | 2003-02-18 | Biolife, L.L.C. | Method for applying a blood clotting agent |
US20030035825A1 (en) * | 2001-08-01 | 2003-02-20 | Yen-Kuen Shiau | Therapeutic pad and a method for treatment of common illnesses |
US6680073B1 (en) * | 1999-04-08 | 2004-01-20 | Bryon J. Tarbet | Composition and method for the treatment of onychomycosis in animals |
US6682720B2 (en) * | 2002-04-25 | 2004-01-27 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Zinc citrate beads in oral compositions |
US20040022863A1 (en) * | 2002-07-31 | 2004-02-05 | Hamtini Samir I. | Topical medicament for treating nappy rash |
US20040028708A1 (en) * | 2002-08-08 | 2004-02-12 | Brooks Joann | Enzyme blocking skin protectant cream |
US20040033270A1 (en) * | 2000-12-18 | 2004-02-19 | Christian Kropf | Nano-sized zinc oxide in hygiene products |
US6696071B2 (en) * | 2001-11-27 | 2004-02-24 | Patrick D. Kelly | Pre-coital and post-coital rinse with anti-viral and skin-protective zinc salts |
US20040037910A1 (en) * | 1992-11-06 | 2004-02-26 | Hon David N. S. | Compositions of oak bark extract, related syntheic compositions and method of using same |
US6844012B1 (en) * | 1998-08-31 | 2005-01-18 | Xavier Forceville | Use of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing said treatment |
US6849277B2 (en) * | 2001-10-09 | 2005-02-01 | Juan Carlos Roig | Composition for moist skin |
US20050032751A1 (en) * | 2003-08-04 | 2005-02-10 | Bing Wang | Methods for treatment of dermatological conditions |
US6855341B2 (en) * | 2002-11-04 | 2005-02-15 | Jeffrey B. Smith | Anti-viral compositions and methods of making and using the anti-viral compositions |
US20050143324A1 (en) * | 2002-04-09 | 2005-06-30 | Sinclair Pharmaceuticals, Ltd. | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye |
US6989156B2 (en) * | 2001-04-23 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Therapeutic treatments using the direct application of antimicrobial metal compositions |
US6992203B2 (en) * | 2002-03-26 | 2006-01-31 | Jh Biotech, Inc. | Metal complexes produced by Maillard Reaction products |
US20060029682A1 (en) * | 2001-11-29 | 2006-02-09 | Greystone Medical Group, Inc. | Treatment of wounds and compositions employed |
US20060036007A1 (en) * | 2004-08-12 | 2006-02-16 | King Industries, Inc. | Organometallic compositions and coating compositions |
US20060052438A1 (en) * | 2004-04-30 | 2006-03-09 | Chi-Tang Ho | Bioactive compounds and methods of uses thereof |
US20070032751A1 (en) * | 2005-08-03 | 2007-02-08 | Sea And Land Therapies, Llc | Filled full shell massage implement |
US7375243B2 (en) * | 2002-12-05 | 2008-05-20 | Md Bioalpha Co., Ltd. | Method for preparation of amino acid chelate |
US7838042B2 (en) * | 2004-04-21 | 2010-11-23 | Albion International, Inc. | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Family Cites Families (351)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US238015A (en) | 1881-02-22 | Ointment | ||
US143133A (en) | 1873-09-23 | Improvement in medical compounds or powders for infants | ||
US232807A (en) | 1880-10-05 | Herbert e | ||
US81008A (en) | 1868-08-11 | Improved eye-wateb | ||
US55889A (en) | 1866-06-26 | Improved eye-water | ||
US411657A (en) | 1889-09-24 | Lotion | ||
US320836A (en) | 1885-06-23 | Ointment | ||
US149857A (en) | 1874-04-21 | Improvement in medical compounds or liniments | ||
US318468A (en) | 1885-05-19 | Eye remedy | ||
US81711A (en) | 1868-09-01 | Improved m medical compound for treating horses, cattle | ||
US93300A (en) | 1869-08-03 | Improved eye-sirup | ||
US229014A (en) | 1880-06-22 | Salve | ||
US415208A (en) | 1889-11-19 | Ointment | ||
US432611A (en) | 1890-07-22 | Salve | ||
US514838A (en) * | 1894-02-13 | Nitro compound and process of making same | ||
US145749A (en) | 1873-12-23 | Improvement in medical compounds or eye-washes | ||
US264783A (en) | 1882-09-19 | Eye-wash | ||
US128385A (en) | 1872-06-25 | Improvement in medical compounds | ||
US127925A (en) | 1872-06-11 | Improvement in medical compounds for treating ringworm | ||
US992937A (en) | 1911-05-23 | Brodbeck Company | Nursery-powder compound. | |
US430048A (en) | 1890-06-10 | Medical bandage | ||
US277221A (en) | 1883-05-08 | Cosmetic wash | ||
US92065A (en) | 1869-06-29 | Improved compound to be used in the cure op rheumatism | ||
US116875A (en) | 1871-07-11 | Improvement in medical compounds | ||
US209331A (en) | 1878-10-29 | Improvement in medical compounds | ||
US140768A (en) | 1873-07-15 | Improvement in eye-washes | ||
US88973A (en) | 1869-04-13 | Improved salve for cure of foot-rot in sheep | ||
US3184376A (en) | 1965-05-18 | Method of producing antiseptic composition | ||
US627296A (en) | 1899-06-20 | Arthur camnitzer | ||
US284335A (en) | 1883-09-04 | Eye-water | ||
US928539A (en) | 1908-04-16 | 1909-07-20 | Gennaro Pucciarelli | Lotion. |
US944738A (en) | 1909-08-16 | 1909-12-28 | Windeler Loose | Medicament for diseases of the mucous membrane. |
US1059841A (en) | 1912-09-23 | 1913-04-22 | Henry Crookes | Production of colloidal metals. |
US1627963A (en) | 1920-01-30 | 1927-05-10 | Henry C Fuller | Medicinal product |
US1411577A (en) | 1921-02-23 | 1922-04-04 | Ervin L Mullins | Ointment |
US1488097A (en) | 1922-03-09 | 1924-03-25 | Henry N Creger | Dentifrice |
US1593485A (en) | 1925-06-29 | 1926-07-20 | Crosnier Georges Eugene Edme | Antiseptic product |
US1584173A (en) | 1925-12-05 | 1926-05-11 | Albert C Holzapfel | Antiseptic |
US1809082A (en) | 1927-05-04 | 1931-06-09 | Epstein & Harris | Product for treating the skin |
US1908176A (en) | 1929-05-28 | 1933-05-09 | Chemical Foundation Inc | Process of making a purified coal tar ointment |
US2002829A (en) | 1929-05-28 | 1935-05-28 | Chemical Foundation Inc | Medicinal preparation |
US2153653A (en) | 1932-01-05 | 1939-04-11 | Stux Gustav | Irradiated dusting powder |
US1982148A (en) | 1932-08-22 | 1934-11-27 | Jr Angel Zimbron | Medicament for external use and method of producing the same |
US2054989A (en) | 1933-12-30 | 1936-09-22 | Us Ind Alcohol Co | Compositions for application to the human skin |
US2087162A (en) | 1935-11-25 | 1937-07-13 | Us Ind Alcohol Co | Perspiration-inhibiting composition |
US2095092A (en) | 1936-02-21 | 1937-10-05 | Clorox Chemical Co | Ointment |
US2129836A (en) | 1936-07-02 | 1938-09-13 | Cosmetic Res Inc | Cosmetic cream rase |
US2114490A (en) | 1937-09-27 | 1938-04-19 | Benjamin R Harris | Emulsion |
US2267739A (en) | 1938-04-05 | 1941-12-30 | George B White | Composition of matter for treating skin diseases |
US2289125A (en) | 1938-04-18 | 1942-07-07 | Wilfred B Kell | Therapeutic agent for the treatment of fungus infection |
US2254636A (en) | 1938-05-11 | 1941-09-02 | Verl D Vangunten | Medicinal product |
US2223142A (en) | 1938-07-11 | 1940-11-26 | C B Dolge Company | Fungicidal preparation |
US2241331A (en) | 1939-01-27 | 1941-05-06 | Wm S Merrell Co | Suppository |
US2299604A (en) | 1939-12-01 | 1942-10-20 | C B Doige Company | Fungicidal composition |
US2372807A (en) | 1941-07-05 | 1945-04-03 | Atlas Powder Co | Absorption bases |
US2361161A (en) | 1943-09-21 | 1944-10-24 | Anderson David Charles | Basic filling for tooth cavities |
US2420389A (en) | 1944-05-18 | 1947-05-13 | Bernard V Travis | Insect repellent composition |
US2420271A (en) | 1944-05-18 | 1947-05-06 | Bernard V Travis | Insect repellent composition |
US2527686A (en) | 1945-12-26 | 1950-10-31 | Max H Sandberg | Mouthwash |
US2469228A (en) | 1946-02-18 | 1949-05-03 | Samuel I Gertler | Insect repellent |
US2649398A (en) | 1949-04-01 | 1953-08-18 | Tampax Inc | Douche composition |
US2556567A (en) | 1949-04-01 | 1951-06-12 | Tampax Inc | Douche composition |
US2652355A (en) | 1950-01-31 | 1953-09-15 | Warner Hudnut Inc | Fungicides |
US2602039A (en) | 1950-05-24 | 1952-07-01 | Dome Chemicals Inc | Crude coal tar dermatological compositions |
US2846322A (en) | 1952-04-29 | 1958-08-05 | Edgar Schaefer | Bactericidal dental cements |
US2748781A (en) | 1953-08-24 | 1956-06-05 | Collat Edgar | Means for dental hygiene |
US2838440A (en) | 1953-10-29 | 1958-06-10 | Rohm & Haas | Dusting powder of carboxylic cationexchange resin and powder base |
US2843522A (en) | 1953-11-17 | 1958-07-15 | Sterling Drug Inc | Peri-anal ointment |
US3137622A (en) | 1957-12-23 | 1964-06-16 | Kline | Topical therapeutic composition |
US3035988A (en) | 1958-03-19 | 1962-05-22 | Dover Chemical Corp | Method of forming friction film on hand |
US2991224A (en) | 1958-08-18 | 1961-07-04 | Dale V Bell | Gingival pack |
NL99185C (en) | 1959-07-30 | |||
US3084105A (en) | 1959-12-18 | 1963-04-02 | Morey E Slodki | Dispersants comprising phosphoric acid monoesters of mannose polymers |
US3013883A (en) | 1960-10-17 | 1961-12-19 | Clyde J Welcker | Process for chemically opening bivalves |
US3033755A (en) | 1961-04-14 | 1962-05-08 | Kolmar Laboratories | Process for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom |
US3146168A (en) | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
US3210248A (en) | 1963-09-04 | 1965-10-05 | Merck & Co Inc | Emollient gel comprising lanolin alcohol, microcrystalline wax and a liqquid fatty acid ester |
US3255079A (en) | 1963-06-17 | 1966-06-07 | American Cyanamid Co | Therapeutic dental cement and a method for treating carious teeth |
US3215599A (en) | 1963-07-02 | 1965-11-02 | Warner Lambert Pharmaceutical | Process for preparing polymer waxmodified petroleum oil unctuous base |
US3317372A (en) | 1965-09-29 | 1967-05-02 | Una L Hart | Household deodorant |
US3590123A (en) | 1967-03-09 | 1971-06-29 | Rewo Chem Fab Gmbh | Human hair,skin and nail treatment with sulfosuccinate compositions |
US3903268A (en) | 1968-02-12 | 1975-09-02 | Lescarden Ltd | Chitin and chitin derivatives for promoting wound healing |
US3826845A (en) | 1969-02-08 | 1974-07-30 | Sankyo Co | Ointment base |
US3821371A (en) | 1970-02-02 | 1974-06-28 | Avicon Inc | Pharmaceutical compositions containing microcrystalline collagen,a water-insoluble,ionizable,partial salt of collagen |
US3749772A (en) | 1970-12-04 | 1973-07-31 | Univ Akron | Dermal protective film |
US3821370A (en) | 1971-03-11 | 1974-06-28 | L Tenta | Topical composition for treating seborrheic keratosis |
US3949072A (en) | 1971-03-11 | 1976-04-06 | Tenta Louis T | Topical composition for treatment of seborrheic keratosis |
US4298601A (en) | 1972-03-06 | 1981-11-03 | Technutra, S.A. | Method and formulations for the treatment of obesity |
US3896238A (en) | 1972-04-05 | 1975-07-22 | Procter & Gamble | Dermatological compositions |
US3856941A (en) | 1972-05-23 | 1974-12-24 | Sobel J | Astringent gel, its preparation and use |
US4048300A (en) | 1973-01-11 | 1977-09-13 | Colgate-Palmolive Company | Dental preparation containing materials having calcium and phosphate components |
US4100269A (en) | 1973-06-28 | 1978-07-11 | Lever Brothers Company | Anticalculus dentifrice |
US4054596A (en) * | 1975-03-07 | 1977-10-18 | Minnesota Mining And Manufacturing Company | Carboxy and carbohydrocarbyloxy-substituted 1,1-bis(perfluoroalkylsulfonyl)propanes |
US4062937A (en) * | 1976-03-12 | 1977-12-13 | La Verne Rea | Insect bite relief preparation |
US4129510A (en) * | 1976-04-28 | 1978-12-12 | The Lubrizol Corporation | Sulfur-containing compounds and lubricants and fuels containing them |
US4166108A (en) | 1977-01-31 | 1979-08-28 | Robert Brown | Styptic composition |
LU77562A1 (en) | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | METHOD FOR PRODUCING NEW PHARMACEUTICAL PREPARATIONS |
US4331653A (en) | 1977-08-18 | 1982-05-25 | Robert Brown | Composition for a topical cream for curtailing bleeding and treating skin disorders |
US4273763A (en) | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
US4444755A (en) | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4160821A (en) | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
US4154911A (en) * | 1978-06-12 | 1979-05-15 | Mooney Chemicals, Inc. | Elastomers with improved metal adhesion |
US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
US4229437A (en) | 1978-07-18 | 1980-10-21 | Lucille Likens Filson | Paste or dough-like salve for treating skin |
US4161526A (en) | 1978-07-20 | 1979-07-17 | Sterling Drug Inc. | Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions |
US4229430A (en) | 1978-08-21 | 1980-10-21 | Fahim Mostafa S | Oral composition for improving oral health |
US4226889A (en) | 1978-12-19 | 1980-10-07 | Dragoco, Inc. | Cosmetic stick composition |
JPS55106543A (en) * | 1979-02-10 | 1980-08-15 | Mitsubishi Gas Chem Co Inc | Preparation of catalyst for synthesizing methanol |
US4226851A (en) | 1979-07-11 | 1980-10-07 | Sompayrac Hewitt A | Stable dental composition containing hydrogen peroxide |
US4335110A (en) | 1979-08-23 | 1982-06-15 | Orewa Inc. | Pharmaceutical compositions of sanguinaria galangal and zinc chloride |
US4330527A (en) | 1979-11-13 | 1982-05-18 | Teruo Arima | Wound treatment agent |
US4512978A (en) | 1980-01-24 | 1985-04-23 | Inwood Louis R | Dermatological composition useful in the treatment of psoriasis |
US4349536A (en) | 1980-03-11 | 1982-09-14 | Hausler Kenneth J | Method of promoting suntan using a cream containing zinc and copper salts |
JPS56139423A (en) | 1980-04-02 | 1981-10-30 | Toyo Seiyaku Kasei Kk | Hemostatic agent for dental oral use |
US4291025A (en) | 1980-04-11 | 1981-09-22 | Laclede Professional Products, Inc. | Agar gel topical dressing |
DE3018969A1 (en) | 1980-05-17 | 1981-11-26 | Beiersdorf Ag, 2000 Hamburg | MIXTURE FOR SEMI-STARRED MEDICAL SUPPORT, MEDICAL GIRL OBTAINED THEREFOR, AND METHOD FOR THE PRODUCTION THEREOF |
US4406881A (en) | 1980-05-20 | 1983-09-27 | Vipont Laboratories | Antimicrobial agent |
GB2080682B (en) | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
GB2084870B (en) | 1980-10-10 | 1985-05-09 | Muhlemann R Hans | Oral compositions containing pyrimidine amine compounds and zinc salts |
US4477439A (en) | 1981-04-13 | 1984-10-16 | Walter J. Monacelli | Treatment of irritated and excoriated areas around the stoma of ostomy patients |
US4515779A (en) | 1981-10-23 | 1985-05-07 | Arkansas Medical Research & Development Corporation | Skin tumor removal and healing compositions and processes |
US4678664A (en) | 1982-09-30 | 1987-07-07 | Basf Corporation | Mineral oil gels |
ZA837627B (en) | 1982-10-15 | 1984-06-27 | Procter & Gamble | Storage stable topical pharmaceutical composition containing low dielectric solvents |
DE3307382C2 (en) | 1983-03-02 | 1990-01-25 | Hans-Peter 8022 Grünwald Walter | Medicinal product suitable for the treatment of inflammatory changes in the bronchial mucosa |
HU190723B (en) | 1983-06-03 | 1986-10-28 | Caola Kozmetikai | Cosmetical composition containing protein-trace element adducts and process for producing them |
JPS6028999A (en) | 1983-06-30 | 1985-02-14 | Maruho Kk | Protein having cell proliferation accelerating action, its composition and its preparation |
NZ210840A (en) | 1984-01-18 | 1987-05-29 | Johnson & Johnson Baby Prod | Composition comprising synergistic combination of miconazole nitrate and zinc oxide |
US4622248A (en) * | 1984-04-04 | 1986-11-11 | Osmose Wood Preserving Co. Of America, Inc. | Preservative composition for wood |
US4661354A (en) | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
US4708864A (en) * | 1984-12-14 | 1987-11-24 | National Research Laboratories | Method and compositions for treating dental structures |
US4760051A (en) | 1985-01-24 | 1988-07-26 | Pickart Loren R | Use of GHL-Cu as a wound-healing and anti-inflammatory agent |
US4937230A (en) | 1985-01-24 | 1990-06-26 | Procyte Corporation | Method of healing wounds in horses |
US5214032A (en) | 1985-02-08 | 1993-05-25 | Procyte Corporation | GHL-CU pharmaceutical compositions and compounds |
US4665054A (en) | 1985-02-08 | 1987-05-12 | Bioheal, Inc. | Chemical derivatives of GHL-Cu |
US4877770A (en) | 1985-02-08 | 1989-10-31 | Procyte Corporation | Chemical derivatives of GHL-Cu |
US5550183A (en) | 1985-02-08 | 1996-08-27 | Procyte Corporation | Metal-peptide compositions and methods for stimulating hair growth |
US4767753A (en) | 1985-02-08 | 1988-08-30 | Procyte Corporation | Methods and compositions for preventing ulcers |
US5348943A (en) | 1985-02-08 | 1994-09-20 | Procyte Corporation | Cosmetic and skin treatment compositions |
US5120831A (en) | 1985-02-08 | 1992-06-09 | Procyte Corporation | Metal-peptide compositions |
US5154932A (en) | 1985-07-05 | 1992-10-13 | The Dow Chemical Company | Antimicrobial positively charged particles |
US4683133A (en) | 1985-08-20 | 1987-07-28 | Vipont Laboratories, Inc. | Method for treating periodontal disease |
US4713242A (en) | 1985-11-07 | 1987-12-15 | Tecma Laboratories, Inc. | Skin therapeutic mixture containing eupatorium extract |
US4847083A (en) | 1986-04-02 | 1989-07-11 | Dermasciences, Inc. | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith |
US4863987A (en) | 1986-04-07 | 1989-09-05 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Deodorizing coating formulations and deodorizing sheets making use of same |
US4855138A (en) | 1986-06-24 | 1989-08-08 | Tecma Laboratories, Inc. | Skin therapeutic mixture containing matico extract |
US4830716B1 (en) * | 1986-07-03 | 1999-12-07 | Albion Int | Preparation of pharmaceutical grade amino acid chelates |
US5385938B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using glycolic acid for treating wrinkles |
US4874361A (en) | 1986-12-29 | 1989-10-17 | Obagi Zein E | Method for healing damaged skin |
US5166176A (en) | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
DE3851203T2 (en) | 1987-05-11 | 1994-12-15 | Procyte Corp | Use of GHL-Cu derivatives in the manufacture of a medicament to stimulate hair growth. |
US5093099A (en) | 1987-11-16 | 1992-03-03 | Kao Corporation | Flaky powder of zinc oxide and its composition for external use |
US4849211A (en) | 1988-03-16 | 1989-07-18 | Schrauzer Gerhard N | Product and method for the treatment of acne and other skin disorders |
US4938969A (en) | 1988-11-14 | 1990-07-03 | Milor Scientific, Ltd. | Method for the treatment of aging or photo-damaged skin |
US4956354A (en) | 1988-12-06 | 1990-09-11 | Thomas G. Kottke | Therapeutic preparation for use on skin |
GB8902300D0 (en) | 1989-02-02 | 1989-03-22 | Bryce Smith Derek | Antirhinoviral preparations |
US5232691A (en) | 1989-04-26 | 1993-08-03 | Lemole Gerald M | Protective gel composition |
US5209932A (en) | 1989-05-30 | 1993-05-11 | Moleculon, Inc. | Foot care compositions |
US5624675A (en) | 1989-06-06 | 1997-04-29 | Kelly; Patrick D. | Genital lubricants containing zinc salts to reduce risk of HIV infection |
US5000944A (en) | 1989-06-09 | 1991-03-19 | Colgate-Palmolive Company | Zinc-containing oral products with reduced astringency |
JPH03108490A (en) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
IL91047A (en) | 1989-07-19 | 1993-06-10 | Yissum Res Dev Co | Zinc complexes for the treatment of free radical- induced diseases |
US5023237A (en) | 1989-08-30 | 1991-06-11 | Procyte Corporation | Methods and compositions for healing ulcers |
US5145838A (en) | 1989-08-30 | 1992-09-08 | Procyte Corporation | Methods and compositions for healing ulcers |
US5554647A (en) | 1989-10-12 | 1996-09-10 | Perricone; Nicholas V. | Method and compositions for treatment and/or prevention of skin damage and aging |
US5059588A (en) | 1989-10-13 | 1991-10-22 | Procyte Corporation, Incorporated | Methods and compositions for healing bone using gly his lys: copper |
US5075019A (en) * | 1989-12-14 | 1991-12-24 | Exxon Chemical Patents Inc. | Low sediment method for preparing copper salts of polyolefinic-substituted dicarboxylic acids |
US5104644A (en) | 1990-02-07 | 1992-04-14 | 7-L Corporation | Mouthrinse composition |
US5310546A (en) | 1990-02-07 | 1994-05-10 | 7-L Corporation | Mouthrinse and method of preparation |
US5174990A (en) | 1990-02-07 | 1992-12-29 | 7-L Corporation | Mouthrinse and method of preparation |
US5118665A (en) | 1990-02-09 | 1992-06-02 | Procyte Corporation | Anti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof |
US5164367A (en) | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
US6103273A (en) | 1990-07-03 | 2000-08-15 | Antoun; Jacques | Pharmaceutical composition comprising starch, a compound comprising boron, a compound comprising zinc, and water, and a method of using same to encourage hair growth |
US5401730A (en) | 1990-07-06 | 1995-03-28 | The Hope Heart Institute | Method for reducing platelet aggregation |
US5165914A (en) | 1991-03-04 | 1992-11-24 | David G. Vlock | Oral compositions containing zinc lactate complexes |
FR2675997B1 (en) | 1991-05-03 | 1993-12-24 | Oreal | TOPICAL ANTI FREE RADICAL COMPOSITION BASED ON SUPEROXIDE DISMUTASE AND A PHOSPHONIC DERIVATIVE. |
US5980477A (en) | 1991-07-29 | 1999-11-09 | Patrick Kelly | Genital lubricants with zinc salts as anti-viral additives |
FR2679775B1 (en) | 1991-08-01 | 1994-11-18 | Grimbert Georges | MEDICAMENT BASED ON NEUTRALIZED SULFUR DERIVATIVES. |
GB9117140D0 (en) | 1991-08-08 | 1991-09-25 | Unilever Plc | Treatment of periodontitis |
US5244651A (en) | 1991-09-04 | 1993-09-14 | Kao Corporation | Method of desensitizing hypersensitive dentin |
TW233264B (en) * | 1992-02-03 | 1994-11-01 | Otsuka Pharma Co Ltd | |
DE4205828A1 (en) | 1992-02-26 | 1993-09-02 | Henkel Kgaa | VIRUSIVE DISINFECTANT |
US5696169A (en) | 1992-03-13 | 1997-12-09 | Otsuka Pharmaceutical Co., Ltd. | Antibacterial and antifungal activity method, therapeutic method of infectious diseases and preserving method of cosmetics |
US5227156A (en) | 1992-04-14 | 1993-07-13 | Amway Corporation | Use of zinc compounds to stabilize a thiazolinone preservative in an anti-dandruff shampoo |
US5688492A (en) | 1992-05-22 | 1997-11-18 | The Boots Company Plc, | Oral hygiene composition |
US6221403B1 (en) | 1992-08-08 | 2001-04-24 | Seton Healthcare Group Plc | Topical composition |
DE4231622C2 (en) | 1992-09-22 | 1996-09-05 | Bakelite Ag | Process for the production of metal neutral complexes with a high coordination number and their use |
FR2697161B1 (en) | 1992-10-26 | 1995-01-13 | Jouvance Daniel | Cosmetic product with stabilized redox potential. |
ATE191850T1 (en) | 1992-11-06 | 2000-05-15 | Greystone Medical Group Inc | OAK BARK EXTRACT-RELATED SYNTHETIC PREPARATIONS AND METHODS OF USE |
US5468860A (en) | 1992-11-19 | 1995-11-21 | Merck & Co., Inc. | New finasteride processes |
WO1994015216A1 (en) | 1992-12-23 | 1994-07-07 | Niyazmatov Agzamdzhan Akhtamov | Process for obtaining a diagnostic reagent for detecting antigens and antibodies of infectious and other illnesses |
EP0697861B1 (en) | 1993-05-13 | 1998-08-26 | Unilever N.V. | Oral compositions containing triclosan for the treatment of aphthous ulcers |
US5330748A (en) | 1993-05-19 | 1994-07-19 | Church & Dwight Co., Inc. | Dentifrices containing zinc oxide particles |
US5302373A (en) | 1993-06-10 | 1994-04-12 | Church & Dwight Co., Inc. | Liquid mouthwash containing a particulate bicarbonate suspension |
US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
US5496539A (en) * | 1993-07-22 | 1996-03-05 | The Procter & Gamble Company | Oral compositions |
US5663213A (en) | 1994-02-28 | 1997-09-02 | Rohm And Haas Company | Method of improving ultraviolet radiation absorption of a composition |
FR2717079B1 (en) | 1994-03-11 | 1996-04-12 | Oreal | Composition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetic and / or dermatological field and methods using it. |
US5504055A (en) * | 1994-03-15 | 1996-04-02 | J.H. Biotech, Inc. | Metal amino acid chelate |
FR2719481B1 (en) | 1994-05-05 | 1996-05-31 | Oreal | Composition based on antifungal compounds and halogenated antibacterial compounds to reduce hair loss. |
US5645840A (en) | 1994-05-25 | 1997-07-08 | Church & Dwight Co., Inc. | Ultrafine sodium bicarbonate powder |
DE69531705T2 (en) | 1994-06-06 | 2004-03-18 | Nippon Shokubai Co. Ltd. | Fine zinc oxide particles, process for their preparation and their use |
US5632972A (en) | 1994-06-30 | 1997-05-27 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method for treating gingival and periodontal tissues |
US5686083A (en) | 1994-12-08 | 1997-11-11 | Schering-Plough Healthcare Products Inc. | Compositions for treating corns and calluses |
FR2728163A1 (en) | 1994-12-20 | 1996-06-21 | Oreal | STABLE COSMETIC, DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION CONTAINING SELENIUM DISULPHIDE AND AT LEAST ONE ZINC SALT |
GB9502253D0 (en) | 1995-02-06 | 1995-03-29 | Giltech Ltd | The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro |
JPH08245741A (en) * | 1995-03-09 | 1996-09-24 | Mitsui Toatsu Chem Inc | Production of integrally skinned polyurethane foam |
US5552147A (en) | 1995-04-25 | 1996-09-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Petroleum jelly with alpha hydroxy carboxylic acids |
US5951990A (en) | 1995-05-15 | 1999-09-14 | Avon Products, Inc. | Ascorbyl-phosphoryl-cholesterol |
US5747005A (en) | 1995-08-02 | 1998-05-05 | Barels; Ronald R. | Oil-based, anti-plaque dentifrice composition |
US5631013A (en) | 1995-08-07 | 1997-05-20 | Church & Dwight Co., Inc. | Cosmetic deodorant products containing encapsulated co-micronized bicarbonate ingredient |
RU2188029C2 (en) | 1995-09-07 | 2002-08-27 | Л'Ореаль | Application of extract out of nonphotosynthetic bacterium and extract-containing composition |
US6750209B1 (en) | 1995-09-12 | 2004-06-15 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5827884A (en) | 1995-09-15 | 1998-10-27 | Omp Acquisition Corporation | Skin peel maintenance composition and method |
EP0880561B1 (en) | 1995-11-06 | 2003-01-08 | M & J Bos Consultants Pty. Ltd. | Uv absorbing compositions |
FR2747044B1 (en) | 1996-04-03 | 1998-06-26 | Coletica | USE OF PLANT SEEDS AFTER GERMINATION AS A SOURCE OF SUPEROXIDE DISMUTASE AND COSMETIC, PHARMACEUTICAL OR AGRI-FOOD COMPOSITIONS CONTAINING SUCH A PLANT SUPEROXIDE DISMUTASE, AND EXTRACTION PROCESS |
US5762945A (en) | 1996-04-05 | 1998-06-09 | Ashley; Eline | Composition and method for treating diaper rash |
JP2822317B2 (en) | 1996-04-15 | 1998-11-11 | 日鉄鉱業株式会社 | Antibacterial titania and method for producing the same |
US5928659A (en) * | 1996-06-07 | 1999-07-27 | Moy; Lawrence S. | Cosmetic formulation and method for amelioration of skin keratoses and striae distensae |
US5955067A (en) | 1996-07-23 | 1999-09-21 | Oge; Eray | Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea |
US6040333A (en) | 1996-07-30 | 2000-03-21 | Energetics, Inc. | Dietary supplements |
US5698184A (en) | 1996-08-23 | 1997-12-16 | Skin Biology, Inc. | Compositions and methods for skin tanning and protection |
US5888522A (en) | 1996-08-23 | 1999-03-30 | Skin Biology, Inc. | Tissue protective and regenerative compositions |
US5837270A (en) | 1996-08-26 | 1998-11-17 | Burgess; Nelson Leon | Topical anti-acne composition |
US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
DE69738654T2 (en) | 1996-10-23 | 2009-06-04 | Daito Kasei Kogyo Co., Ltd. | ZINC OXIDE POWDER WITH LOW-EFFECT AND COSMETICS COMPOSITION |
US5882638A (en) | 1996-10-24 | 1999-03-16 | The Proctor & Gamble Company | Methods using uncomplexed cyclodextrin solutions for controlling environmental odors |
US5879666A (en) | 1996-10-24 | 1999-03-09 | The Procter & Gamble Company | Methods and compositions for reducing body odor |
US5897855A (en) | 1996-10-24 | 1999-04-27 | The Procter & Gamble Company | Methods and compositions for reducing body odor |
US5911976A (en) | 1996-10-24 | 1999-06-15 | The Procter & Gamble Company | Compositions for reducing body odor |
US5897856A (en) | 1996-10-24 | 1999-04-27 | The Procter & Gamble Company | Methods and compositions for reducing body odor |
US5780020A (en) | 1996-10-28 | 1998-07-14 | The Proctor & Gamble Company | Methods and compositions for reducing body odor |
FR2779059B1 (en) * | 1998-05-29 | 2004-09-10 | Guerlain | COSMETIC TREATMENT PROCESS FOR COMBATING THE EFFECTS OF CUTANEOUS AGING; NEW COSMETIC COMPOSITIONS FOR ITS IMPLEMENTATION |
US6471972B1 (en) | 1996-11-07 | 2002-10-29 | Lvmh Recherche | Cosmetic treatment method for fighting against skin ageing effects |
WO1998021166A1 (en) * | 1996-11-13 | 1998-05-22 | Stoller Enterprises, Inc. | Fertilizer compositions including chelated metal ions |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US6046178A (en) * | 1997-04-18 | 2000-04-04 | Deroyal Industries, Inc. | Method and compound for treating wounds with starch hydrolysate medication |
US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6071543A (en) | 1997-06-02 | 2000-06-06 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols reverse mucocutaneous aging |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US5897854A (en) | 1997-06-09 | 1999-04-27 | The Procter & Gamble Company | Methods for reducing body odor |
US5942214A (en) | 1997-06-09 | 1999-08-24 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume |
US6331567B1 (en) | 1997-06-13 | 2001-12-18 | Mars Uk Limited | Edible composition containing zinc and linoleic acid |
JP3848742B2 (en) | 1997-07-03 | 2006-11-22 | メルク株式会社 | UV shielding pigment |
US6248370B1 (en) | 1997-07-24 | 2001-06-19 | Leroy Harris | Skin treatment and methods |
US6224896B1 (en) | 1997-07-28 | 2001-05-01 | Curlor Healthcare Technologies, Llc | Composition and process for the treatment of epidermal traumas such as decubitus ulcers |
US5874094A (en) | 1997-08-05 | 1999-02-23 | Costello; Jeremiah | Cream formulation for topical application |
US5948390A (en) | 1997-08-25 | 1999-09-07 | Pfizer Inc. | Stable zinc/citrate/CPC oral rinse formulations |
JP4034430B2 (en) | 1997-09-10 | 2008-01-16 | 三好化成株式会社 | Organosilicon compound-treated powder base material, method for producing the same, and cosmetics containing the base material |
DK176196B1 (en) * | 1997-10-07 | 2007-01-08 | Ejvind Jersie Pedersen | Oral hygiene composition for the treatment of halitosis and the use of a chelate comprising a metal ion moiety and an amino acid moiety as a component of the composition |
US6113636A (en) | 1997-11-20 | 2000-09-05 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
US5928658A (en) | 1997-12-05 | 1999-07-27 | U.S. Cosmetics | Oil-free wax-free solid cosmetic composition |
US5994403A (en) | 1997-12-17 | 1999-11-30 | Donatiello; Steven T. | Tannin (tannic acid) treatment of athlete's foot and other fungal infections |
US6197815B1 (en) * | 1998-03-18 | 2001-03-06 | J.H. Biotech, Inc. | Amino acid chelates to reduce still births and increase birth weight in non-human animals |
FR2777178B1 (en) | 1998-04-10 | 2000-06-02 | Oreal | MAKEUP KIT COMBINING A GONIOCHROMATIC PIGMENT AND A SINGLE-COLORED PIGMENT HAVING ONE OF THE COLORS OF GONIOCHROMATIC PIGMENT, USES THEREOF |
EP0960572A1 (en) | 1998-05-12 | 1999-12-01 | N.V. Nutricia | Nutritional composition for the treatment of pressure ulcers |
US20030190371A1 (en) | 1998-05-21 | 2003-10-09 | The Boots Company Plc | Antimicrobial agent |
US6123925A (en) | 1998-07-27 | 2000-09-26 | Healthshield Technologies L.L.C. | Antibiotic toothpaste |
US6060079A (en) | 1998-09-09 | 2000-05-09 | Freeman; Frank | Device for topical localized administration of zinc to tissue |
JP2003517442A (en) | 1998-09-23 | 2003-05-27 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Oral care composition |
US6607716B1 (en) | 1998-09-29 | 2003-08-19 | Tech Labs, Inc. | Pediculicidal compositions, a kit, and methods of use |
US5965137A (en) | 1998-11-16 | 1999-10-12 | Advanced Medical Instruments | Insect repellent composition and method for inhibiting the transmission and treatment of symptoms of vector-borne diseases |
FR2787995B1 (en) | 1998-12-30 | 2002-05-03 | Oreal | HYDROPHOBIC ANHYDROUS COSMETIC COMPOSITION IN THE FORM OF COMPACT POWDER |
US6217914B1 (en) | 1999-03-19 | 2001-04-17 | Bioderm, Inc. | Ascorbic acid composition and method for treatment of aging or damaged skin |
EP1162936B1 (en) | 1999-03-23 | 2011-07-13 | Pyramid Productions Inc. | Body coating composition |
CA2272732C (en) | 1999-05-25 | 2008-07-29 | Sylvain Simoneau | Hemorrhoidal treatment composition |
US6558710B1 (en) | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
US7026308B1 (en) | 1999-06-25 | 2006-04-11 | The Procter & Gamble Company | Topical anti-microbial compositions |
JP2001039809A (en) | 1999-07-27 | 2001-02-13 | Tsumoru Shimada | Antibacterial material, deodorant material, repellent material and dehumidification material |
US6627178B1 (en) | 1999-07-30 | 2003-09-30 | Garret D. Cawthon | Methods, compositions and systems for the prevention and treatment of diaper rash |
US7115535B1 (en) | 1999-08-02 | 2006-10-03 | The Procter & Gamble Company | Personal care articles comprising batting |
US6322588B1 (en) | 1999-08-17 | 2001-11-27 | St. Jude Medical, Inc. | Medical devices with metal/polymer composites |
US6375942B1 (en) | 1999-08-31 | 2002-04-23 | Michael C. Rico | Skin healing ointment |
US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
US6303651B1 (en) | 1999-09-23 | 2001-10-16 | Thione International, Inc. | Synergistic antioxidant veterinary compositions |
US20010014356A1 (en) | 1999-12-24 | 2001-08-16 | Yuzo Yoshida | Plasminogen activator inhibitor and external preparation for skin comprising the same |
JP4558122B2 (en) | 2000-01-14 | 2010-10-06 | 株式会社資生堂 | Antibacterial and antifungal agent and antibacterial and antifungal composition |
US6579541B2 (en) | 2000-03-28 | 2003-06-17 | Marantech Holding, Llc | Oxidative fluorinator compounds as antimicrobials |
US6361800B1 (en) | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
ES2272459T3 (en) | 2000-05-08 | 2007-05-01 | Pfizer Products Inc. | SKIN PROTECTIVE SPRAY COMPOSITIONS. |
US20040058015A1 (en) | 2000-06-01 | 2004-03-25 | Yuanjin Tao | Compositions and methods for treating eye discomfort and eye disease |
US6833362B2 (en) | 2000-06-12 | 2004-12-21 | Ward Beryl Bowen, Jr. | Method and composition for the accelerated in vivo removal of ethanol |
AU6689601A (en) | 2000-06-16 | 2002-01-02 | Rtp Pharma Inc | Improved injectable dispersions of propofol |
JP3822782B2 (en) | 2000-07-06 | 2006-09-20 | 三好化成株式会社 | Sebum-adsorbing powder and use thereof |
US20040220100A1 (en) | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20030215412A1 (en) | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US7008647B2 (en) | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
JP2002069051A (en) * | 2000-08-25 | 2002-03-08 | Res Inst For Prod Dev | Method for producing solution of methionine-zinc complex |
AU8618901A (en) | 2000-09-11 | 2002-03-26 | Showa Denko Kk | Cosmetic composition |
TWI292322B (en) | 2000-09-25 | 2008-01-11 | Shiseido Co Ltd | Metal oxide/silica complex and cosmetics containing the same |
JP2002173465A (en) * | 2000-09-29 | 2002-06-21 | Sanyo Chem Ind Ltd | Method for producing condensed dehydration product |
US6710079B1 (en) * | 2000-10-11 | 2004-03-23 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes free of interfering complex ions |
US6426424B1 (en) * | 2000-10-11 | 2002-07-30 | Albion International, Inc. | Composition and method for preparing granular amino acid chelates and complexes |
US6660306B2 (en) | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
GB0029018D0 (en) | 2000-11-28 | 2001-01-10 | Strakan Group Plc | Dermatological formulations |
WO2002064104A1 (en) | 2001-02-15 | 2002-08-22 | Pickart Loren R | Methods for treating fingernails and toenails |
NL1017487C2 (en) | 2001-03-02 | 2002-09-06 | Caral B V I O | Preparation with polydimethylsiloxane for disorders of nails, cartilage, bones, joints, muscles and tendons. |
US6780439B2 (en) | 2001-03-06 | 2004-08-24 | J. Ronald Wilk | Wound treatment solution and method for using same |
JP2002262781A (en) * | 2001-03-09 | 2002-09-17 | Res Inst For Prod Dev | Method for producing composition solution containing transition metal complex and amino acid, additive for fishery feed containing the solution, and feed for fish and shellfish containing the same |
GB2374008B (en) | 2001-04-04 | 2005-03-16 | John Carter | Pharmaceutical compositions comprising copper and zinc |
US6800301B2 (en) | 2001-04-09 | 2004-10-05 | Sadie N. Smith | Multi-purpose skin balm including skin balm for psoriasis |
WO2002089741A2 (en) | 2001-05-04 | 2002-11-14 | Theralife, Inc. | Compositions and methods for enhancing drug delivery |
FR2824474B1 (en) | 2001-05-11 | 2004-01-02 | Fabre Pierre Dermo Cosmetique | COSMETIC COMPOSITION BASED ON SUCRALFATE AND COPPER AND ZINC SULFATES |
US6475526B1 (en) | 2001-06-05 | 2002-11-05 | Jeffrey B. Smith | Zinc containing compositions for anti-viral use |
ES2272730T3 (en) | 2001-06-15 | 2007-05-01 | Innovent Technology Limited | COMPOSITION FOR THE TREATMENT OF DISEASES AFFECTING THE LIVES OF ANIMALS. |
US6416744B1 (en) | 2001-06-21 | 2002-07-09 | Colgate Palmolive Company | Tooth whitening chewing gum |
TNSN02063A1 (en) | 2001-07-07 | 2005-12-23 | Egyptian Natural Oil Co Natoil | The medical effect of jojoba oil |
US6929800B2 (en) | 2001-08-06 | 2005-08-16 | Abdul Rasoul Salman | Nasal passage cleaning composition |
ITMI20011732A1 (en) * | 2001-08-07 | 2003-02-07 | Indena Spa | ORAL PHARMACEUTICAL AND / OR COSMETIC COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HAIR LESS DISORDERS |
US20040076686A1 (en) | 2001-08-10 | 2004-04-22 | Thomas Riesinger | Treatment solution used for caring wounds in addition to dressing material for use with said treatment solution |
ATE332879T1 (en) | 2001-08-22 | 2006-08-15 | Schott Ag | ANTIMICROBIAL, ANTI-INFLAMMATORY, WOUND-HEALING GLASS POWDER AND USE THEREOF |
US6699509B1 (en) | 2001-09-17 | 2004-03-02 | Silvia Melinte | Tattoo removal |
US20030082219A1 (en) | 2001-10-01 | 2003-05-01 | The Procter & Gamble Company | Skin care compositions comprising low concentrations of skin treatment agents |
US20050238730A1 (en) | 2001-11-21 | 2005-10-27 | Agnes Le Fur | Compositions comprising an ethanolamine derivative and organic metal salts |
US20040170703A1 (en) | 2001-11-29 | 2004-09-02 | Greystone Medical Group, Inc. | Reduction of reactive oxygen species in chronic wound management |
ITBS20010111A1 (en) | 2001-12-20 | 2003-06-20 | Paoli Ambrosi Gianfranco De | COMPOSITION FOR TOPICAL USE BASED ON THE ETHYL ESTER OF LINOLEIC ACID AND OF THE TRIETYL ESTER OF CITRIC ACID ASSOCIATED WITH OPPORTUN |
DE10163256A1 (en) | 2001-12-21 | 2003-07-10 | Henkel Kgaa | Surface modified zinc oxide for the production of nanoparticulate dispersions |
US20030161892A1 (en) | 2002-02-27 | 2003-08-28 | Mcfarland Connie L. | Topical clotting ointment and method |
DE10212680A1 (en) | 2002-03-22 | 2003-10-09 | Degussa | Nanoscale zinc oxide, process for its production and use |
US20030194446A1 (en) | 2002-04-10 | 2003-10-16 | Akes Lindy K. | Zinc oxide compositions for dermatheraputics |
US8119168B2 (en) | 2002-04-22 | 2012-02-21 | The Procter & Gamble Company | Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
US20030199488A1 (en) | 2002-04-23 | 2003-10-23 | Trotta Gina M. | Treatment of hyperproliferative disorders/inflammatory dermatoses |
US20030224027A1 (en) | 2002-05-29 | 2003-12-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with ammonium malonates |
US20030224023A1 (en) | 2002-05-29 | 2003-12-04 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with hydroxy amine salts of malonic acid |
AU2003240709B2 (en) * | 2002-05-29 | 2006-03-02 | Unilever Plc | Cosmetic compositions containing salts of malonic acid |
JP2006501159A (en) | 2002-05-31 | 2006-01-12 | ロデイア・シミ | Method for forming carbon-carbon bond or carbon-heteroatom bond |
KR101183075B1 (en) * | 2002-07-01 | 2012-09-20 | 빌라니 마리아 | Porifera-based therapeutic compositions for treating and preventing skin diseases |
US6964782B1 (en) | 2002-07-23 | 2005-11-15 | Tec Labs, Inc. | Stable hydrogen peroxide compositions, products and methods of use |
US7208170B2 (en) | 2002-09-20 | 2007-04-24 | Petersson Lennart G | Powder teat dip germicide, fungicide and skin conditioner |
US6743416B2 (en) | 2002-09-30 | 2004-06-01 | Bonnie Riedl | Sunscreen for animals |
JP3874412B2 (en) | 2002-09-30 | 2007-01-31 | 株式会社資生堂 | Topical skin preparation |
US7129375B2 (en) * | 2002-10-16 | 2006-10-31 | Zinpro Corporation | Metal complexes of α amino dicarboxylic acids |
KR20120008081A (en) | 2002-10-25 | 2012-01-25 | 레반스 테라퓨틱스, 아이엔씨. | Modulation of zinc levels to improve tissue properties |
US20040091551A1 (en) | 2002-11-13 | 2004-05-13 | Al-Karim Damji | Topical composition and application system |
US20040101541A1 (en) | 2002-11-27 | 2004-05-27 | Heffernan Michael Scully | Electrolytic cream |
US6706904B1 (en) | 2002-12-04 | 2004-03-16 | Albion International, Inc. | Dimetalhydroxy malates |
US6979468B1 (en) * | 2002-12-06 | 2005-12-27 | Sirius Laboratories | Oral composition and method for the treatment of inflammatory cutaneous disorders |
US7022351B2 (en) * | 2003-01-14 | 2006-04-04 | Zinpro Corporation | Composition for supplementing animals with solutions of essential metal amino acid complexes |
US20040185015A1 (en) | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Sunscreen cosmetic compositions storage stabilized with malonate salts |
US20040185074A1 (en) | 2003-03-17 | 2004-09-23 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Odor control in amine salt containing cosmetic compositions |
US20040202689A1 (en) | 2003-03-17 | 2004-10-14 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Terpenoid fragrance components stabilized with malonic acid salts |
AU2004249256A1 (en) | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
WO2005002597A1 (en) | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
US20050100571A1 (en) | 2003-11-10 | 2005-05-12 | Larry Keyes | Method and device to treat skin affected by a corn |
US7258875B2 (en) | 2003-12-04 | 2007-08-21 | Chiou Consulting, Inc. | Compositions and methods for topical treatment of skin infection |
US20050175719A1 (en) | 2004-02-05 | 2005-08-11 | Ying Sun | Procyanidins for treatment and prevention of enzymatic irritation to the skin |
US7404949B2 (en) | 2004-03-15 | 2008-07-29 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Methods and compositions useful to prevent in-grown hair arising from shaving |
WO2005120451A1 (en) * | 2004-06-14 | 2005-12-22 | Unilever Plc | Method of decreasing sebum production and pore size |
AU2005299461B2 (en) | 2004-10-25 | 2011-09-01 | National Research Laboratories, Ltd. | Methods for making and using synergistic multifunctional compositions |
PL1993569T3 (en) * | 2006-02-03 | 2014-11-28 | Obagi Cosmeceuticals Llc | Anti-aging treatment using copper and zinc compositions |
US7897800B2 (en) * | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
-
2007
- 2007-01-29 US US11/668,020 patent/US7897800B2/en active Active
- 2007-02-01 MX MX2007001296A patent/MX2007001296A/en active IP Right Grant
- 2007-02-01 CA CA2576640A patent/CA2576640C/en active Active
- 2007-02-02 EP EP07002294.2A patent/EP1816116B3/en active Active
- 2007-02-02 PL PL07002294T patent/PL1816116T6/en unknown
- 2007-02-02 ES ES07002294.2T patent/ES2456142T7/en active Active
- 2007-02-02 KR KR20070011179A patent/KR101509239B1/en active IP Right Grant
- 2007-02-05 JP JP2007025350A patent/JP5469797B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 US US13/011,144 patent/US20110178318A1/en not_active Abandoned
-
2013
- 2013-12-20 JP JP2013263278A patent/JP6033763B2/en active Active
Patent Citations (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US46494A (en) * | 1865-02-21 | Improved eye-water | ||
US51868A (en) * | 1866-01-02 | Improved remedy for sore eyes | ||
US87343A (en) * | 1869-03-02 | Improved medical compound | ||
US124751A (en) * | 1872-03-19 | Improvement in medical compounds or salves | ||
US171875A (en) * | 1876-01-04 | Improvement in cattle-washes | ||
US173607A (en) * | 1876-02-15 | Improvement in deodorizing, disinfecting, and antiseptic powders | ||
US2870151A (en) * | 1959-01-20 | Mqrpholine -ethers | ||
US1086900A (en) * | 1913-02-28 | 1914-02-10 | Kalil David | Remedy for syphilis. |
US1332190A (en) * | 1918-06-21 | 1920-02-24 | Meda Mfg Company | Cosmetic |
US1949797A (en) * | 1929-07-30 | 1934-03-06 | Kaufmann Hans | Process of producing compositions of matter containing sulphur in colloidal distribution |
US1947568A (en) * | 1930-09-27 | 1934-02-20 | Drug Products Co Inc | Carron oil compound chlorinated cream |
US2194218A (en) * | 1936-09-21 | 1940-03-19 | Dickeson Thurstan Wyatt | Stable emulsions of water with liquid or liquefiable substances which are immiscible with water |
US2344830A (en) * | 1940-08-15 | 1944-03-21 | Wisconsin Alumni Res Found | Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal |
US2370561A (en) * | 1941-07-11 | 1945-02-27 | Schuylkill Chemical Co | Therapeutic product and method of making same |
US2673364A (en) * | 1948-05-04 | 1954-03-30 | Twix Inc | Dental cleaning pad |
US2703777A (en) * | 1950-05-02 | 1955-03-08 | Iso Sol Company Inc | Ophthalmological preparations and vehicles and method of making the same |
US2870150A (en) * | 1954-11-29 | 1959-01-20 | Abbott Lab | Morpholine ethers |
US2736681A (en) * | 1955-02-11 | 1956-02-28 | Merck & Co Inc | Chemical compounds |
US2872372A (en) * | 1956-06-08 | 1959-02-03 | Ici Ltd | New indole derivatives |
US3164523A (en) * | 1961-03-22 | 1965-01-05 | Warner Lambert Pharmaceutical | Composition for skin beautification and treatment |
US3366114A (en) * | 1964-06-29 | 1968-01-30 | Saul L. Kanter | Ileostomy appliance |
US4309989A (en) * | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
US4138477A (en) * | 1976-05-28 | 1979-02-06 | Colgate Palmolive Company | Composition to control mouth odor |
US4146607A (en) * | 1977-11-07 | 1979-03-27 | Lever Brothers Company | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc |
US4315916A (en) * | 1978-07-18 | 1982-02-16 | Lucille L. Filson | Topical salve |
US4322400A (en) * | 1978-12-19 | 1982-03-30 | Dragoco Inc. | Cosmetic stick composition |
US4255418A (en) * | 1979-05-14 | 1981-03-10 | Bailey Florence H | Anti-acne lotion |
US4310516A (en) * | 1980-02-01 | 1982-01-12 | Block Drug Company Inc. | Cosmetic and pharmaceutical vehicle thickened with solid emulsifier |
US4376115A (en) * | 1980-08-05 | 1983-03-08 | Mccrorey Howard S | Method and composition for treating teeth and method for preparing same |
US4372296A (en) * | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
US4503037A (en) * | 1981-03-17 | 1985-03-05 | Human Oltoanyagtermel/o/ es Kutato Intezet | Composition for the treatment of epithelial injuries and process for the preparation thereof |
US4375968A (en) * | 1981-07-10 | 1983-03-08 | Manhart Mark J | Therapeutic calcium hydroxide dental preparation and method |
US4430324A (en) * | 1981-11-27 | 1984-02-07 | Lever Brothers Company | Ammonium fluorometallate containing compositions |
US4428933A (en) * | 1982-08-02 | 1984-01-31 | King John R | Composition for treating acne, method of manufacturing said composition, and method of treating skin |
US4568540A (en) * | 1984-04-18 | 1986-02-04 | Johnson & Johnson | Oral hygiene compositions |
US4652444A (en) * | 1984-12-14 | 1987-03-24 | National Research Laboratories | Methods and compositions for treating dental structures |
US5177061A (en) * | 1985-02-08 | 1993-01-05 | Procyte Corporation | Method for stimulating hair growth using GHL-Cu complexes |
US4810693A (en) * | 1985-02-08 | 1989-03-07 | Procyte Corporation | Method for inducing biological coverings in wounds |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
USRE33512E (en) * | 1985-09-11 | 1991-01-01 | Chesebrough-Pond's, Inc. | Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt |
US4654213A (en) * | 1985-09-11 | 1987-03-31 | Cheesebrough-Pond's Inc. | Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt |
US4647452A (en) * | 1985-11-08 | 1987-03-03 | Lever Brothers Company | Oral compositions of salicylamides and zinc salts for the synergistic inhibition of dental plaque |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B1 (en) * | 1986-12-23 | 1995-09-26 | Ruey J Yu | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US4816254A (en) * | 1987-07-29 | 1989-03-28 | Moss Thomas D | Ointment for treating skin irritations |
US4816693A (en) * | 1987-08-21 | 1989-03-28 | National Electrostatics Corp. | Apparatus and method for uniform ion dose control |
US5079010A (en) * | 1988-09-22 | 1992-01-07 | Siegfreid Natterer | Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals |
US5091193A (en) * | 1989-08-23 | 1992-02-25 | Roussel Uclaf | Diaper rash treatment and compositions |
US4992259A (en) * | 1990-01-03 | 1991-02-12 | Johnson & Johnson Consumer Products, Inc. | Stable oral composition of zinc |
US5597552A (en) * | 1991-12-20 | 1997-01-28 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5382431A (en) * | 1992-09-29 | 1995-01-17 | Skin Biology, Inc. | Tissue protective and regenerative compositions |
US20040037910A1 (en) * | 1992-11-06 | 2004-02-26 | Hon David N. S. | Compositions of oak bark extract, related syntheic compositions and method of using same |
US5385727A (en) * | 1993-05-19 | 1995-01-31 | Church & Dwight Co., Inc. | Dentifrices containing zinc oxide particles and sodium bicarbonate |
US5484597A (en) * | 1993-07-30 | 1996-01-16 | Chesebrough-Pond's Usa Co. | Clear hydroalcholic cosmetic microemulsions |
US5480975A (en) * | 1994-02-08 | 1996-01-02 | Brigham And Women's Hospital | Induction of vascular endothelial growth factor (VEGF) by transition metals |
US5858993A (en) * | 1994-03-28 | 1999-01-12 | Skin Biology, Inc. | Starch-metal complexes for skin and hair |
US5708023A (en) * | 1994-03-28 | 1998-01-13 | The Trustees Of Columbia University In The City Of New York | Zinc gluconate gel compositions |
US5482720A (en) * | 1994-10-11 | 1996-01-09 | Church & Dwight Co., Inc. | Encapsulated co-micronized bicarbonate salt compositions |
US5707609A (en) * | 1994-12-09 | 1998-01-13 | Mo; Buxing | Apparatus and method for administering minerals |
US5597550A (en) * | 1994-12-09 | 1997-01-28 | Buxing Mo | Apparatus and method for administering minerals |
US5874067A (en) * | 1996-10-24 | 1999-02-23 | The Procter & Gamble Company | Methods for controlling environmental odors on the body |
US5858371A (en) * | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US6019976A (en) * | 1997-03-26 | 2000-02-01 | Bryant; Andrew Edward | Formulations for treating male pattern baldness containing Serenoa repens, Vitamin B6, Vitamin B3, zinc and L-Arginine |
US6030605A (en) * | 1997-04-03 | 2000-02-29 | Nabisco, Inc. | Breath freshening compositions and methods using them |
US5861143A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Methods for reducing body odors and excess moisture |
US5858335A (en) * | 1997-06-09 | 1999-01-12 | The Procter & Gamble Company | Method of reducing body odor using perfume-free two phase compositions |
US5861146A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method for reducing body odor |
US5871719A (en) * | 1997-06-09 | 1999-02-16 | The Procter & Gamble Company | Perfume-free two phase compositions for reducing body odor |
US5871718A (en) * | 1997-06-09 | 1999-02-16 | The Procter & Gamble Company | Perfumed two phase compositions for reducing body odor |
US5874070A (en) * | 1997-06-09 | 1999-02-23 | The Procter & Gamble Company | Compositions for reducing body odor |
US5861145A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Method of reducing body odor using perfumed, odor absorbing, two phase compositions |
US5861147A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins and perfume |
US5861144A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Perfumed compositions for reducing body odors and excess moisture |
US5855873A (en) * | 1997-10-27 | 1999-01-05 | Church Dwight & Co., Inc. | Stable solution of zinc and bicarbonate ions |
US6190407B1 (en) * | 1997-11-20 | 2001-02-20 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal |
US6022565A (en) * | 1997-12-11 | 2000-02-08 | Albros, L.P. | Rhus dermatitis treatment composition and method |
US6191167B1 (en) * | 1997-12-29 | 2001-02-20 | Tristrata Technology, Inc. | Pharmaceutical compositions containing hydroxycarboxylic acid and/or ketocarboxylic acids and methods of using the same |
US6844012B1 (en) * | 1998-08-31 | 2005-01-18 | Xavier Forceville | Use of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing said treatment |
US6183785B1 (en) * | 1998-11-12 | 2001-02-06 | Geoffrey J. Westfall | Teat disinfectant |
US6680073B1 (en) * | 1999-04-08 | 2004-01-20 | Bryon J. Tarbet | Composition and method for the treatment of onychomycosis in animals |
US6517849B1 (en) * | 1999-10-19 | 2003-02-11 | The Procter & Gamble Company | Tissue products containing antiviral agents which are mild to the skin |
US6521265B1 (en) * | 2000-02-09 | 2003-02-18 | Biolife, L.L.C. | Method for applying a blood clotting agent |
US20020001629A1 (en) * | 2000-03-23 | 2002-01-03 | Voellmy Richard W. | Compositions and methods relating to prevention of chemotherapy-induced alopecia |
US6518240B1 (en) * | 2000-10-11 | 2003-02-11 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes |
US20040033270A1 (en) * | 2000-12-18 | 2004-02-19 | Christian Kropf | Nano-sized zinc oxide in hygiene products |
US20030004564A1 (en) * | 2001-04-20 | 2003-01-02 | Elkins Christopher J. | Drug delivery platform |
US6989156B2 (en) * | 2001-04-23 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Therapeutic treatments using the direct application of antimicrobial metal compositions |
US20030026848A1 (en) * | 2001-07-06 | 2003-02-06 | Joshi Ashok V. | Beneficial materials for topical or internal use by a human or other animal |
US20030035825A1 (en) * | 2001-08-01 | 2003-02-20 | Yen-Kuen Shiau | Therapeutic pad and a method for treatment of common illnesses |
US6849277B2 (en) * | 2001-10-09 | 2005-02-01 | Juan Carlos Roig | Composition for moist skin |
US6696071B2 (en) * | 2001-11-27 | 2004-02-24 | Patrick D. Kelly | Pre-coital and post-coital rinse with anti-viral and skin-protective zinc salts |
US20060029682A1 (en) * | 2001-11-29 | 2006-02-09 | Greystone Medical Group, Inc. | Treatment of wounds and compositions employed |
US6992203B2 (en) * | 2002-03-26 | 2006-01-31 | Jh Biotech, Inc. | Metal complexes produced by Maillard Reaction products |
US20050143324A1 (en) * | 2002-04-09 | 2005-06-30 | Sinclair Pharmaceuticals, Ltd. | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye |
US6682720B2 (en) * | 2002-04-25 | 2004-01-27 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Zinc citrate beads in oral compositions |
US20040022863A1 (en) * | 2002-07-31 | 2004-02-05 | Hamtini Samir I. | Topical medicament for treating nappy rash |
US20040028708A1 (en) * | 2002-08-08 | 2004-02-12 | Brooks Joann | Enzyme blocking skin protectant cream |
US6855341B2 (en) * | 2002-11-04 | 2005-02-15 | Jeffrey B. Smith | Anti-viral compositions and methods of making and using the anti-viral compositions |
US7375243B2 (en) * | 2002-12-05 | 2008-05-20 | Md Bioalpha Co., Ltd. | Method for preparation of amino acid chelate |
US20050032751A1 (en) * | 2003-08-04 | 2005-02-10 | Bing Wang | Methods for treatment of dermatological conditions |
US7838042B2 (en) * | 2004-04-21 | 2010-11-23 | Albion International, Inc. | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
US20060052438A1 (en) * | 2004-04-30 | 2006-03-09 | Chi-Tang Ho | Bioactive compounds and methods of uses thereof |
US20060036007A1 (en) * | 2004-08-12 | 2006-02-16 | King Industries, Inc. | Organometallic compositions and coating compositions |
US20070032751A1 (en) * | 2005-08-03 | 2007-02-08 | Sea And Land Therapies, Llc | Filled full shell massage implement |
Non-Patent Citations (3)
Title |
---|
Lu, T. et al. "Self-assembly of copper and magnesium ions with L-glutamate: spectroscopic and structural properties of [CuMg(L-glutamato)2(H2O)3].2H2O," Polyhedron (1998) 17: 75-79. * |
Mukherjee, G., et al. "Multimetal multiligand complexes. Part II. Equilibrium study on the formation and stability of mixed-metal, mixed-ligand complexes of cobalt-, nickel-, copper- and zinc(II) with aspartate and benzimidazole in aqueous solution," J. Indian Chem. Soc., (2000) 77: 209-212. * |
Yilmaz, V. et al. "Synthesis, spectral, thermal and structural characterization of {[Cu(H2O)3][Cu(MAL)2].2H2O} and [Cu(MAL)(TEA)].H2O(MAL = malonate and TEA = triethanolamine)," Transition Metal Chemistry, (2004) 29:336-42. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012174076A1 (en) * | 2011-06-13 | 2012-12-20 | Jr Chem, Llc | Appliances and compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions |
Also Published As
Publication number | Publication date |
---|---|
MX2007001296A (en) | 2008-10-29 |
JP2014111602A (en) | 2014-06-19 |
CA2576640A1 (en) | 2007-08-03 |
EP1816116A1 (en) | 2007-08-08 |
US20070203354A1 (en) | 2007-08-30 |
EP1816116B3 (en) | 2016-08-03 |
ES2456142T3 (en) | 2014-04-21 |
KR20070079938A (en) | 2007-08-08 |
ES2456142T7 (en) | 2017-04-20 |
JP5469797B2 (en) | 2014-04-16 |
JP2007204479A (en) | 2007-08-16 |
EP1816116B1 (en) | 2013-11-27 |
CA2576640C (en) | 2013-01-22 |
JP6033763B2 (en) | 2016-11-30 |
US7897800B2 (en) | 2011-03-01 |
PL1816116T6 (en) | 2017-12-29 |
KR101509239B1 (en) | 2015-04-06 |
PL1816116T3 (en) | 2014-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7897800B2 (en) | Chemical compositions and methods of making them | |
US8148563B2 (en) | Chemical compositions and methods of making them | |
JP3519108B2 (en) | Esters of L-carnitine and alkanoyl-L-carnitine and pharmaceutical compositions thereof | |
RU2621681C2 (en) | Method | |
HUT72298A (en) | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations thereof and methods for their preparation | |
US9629789B2 (en) | Rosacea treatments using polymetal complexes | |
EP2087880A2 (en) | Compositions, kits and regimens for the treatment of skin, especially décolletage | |
US9427397B2 (en) | Rosacea treatments and kits for performing them | |
EP0024096A2 (en) | Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes | |
US20140248221A1 (en) | Compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions | |
US20120177582A1 (en) | Compositions for anorectal use and methods for treating anorectal disorders | |
US8952057B2 (en) | Compositions for anorectal use and methods for treating anorectal disorders | |
US20140228744A1 (en) | Appliances and compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions | |
US9556113B2 (en) | Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment | |
WO2012174076A1 (en) | Appliances and compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions | |
GB2110209A (en) | Chlorhexidine salt | |
JPH02196791A (en) | Zinc cysteate, its manufacture, and its use for drug and cosmetic | |
DE1119249B (en) | Process for the production of an oxidation-resistant and ferric salt-free monoferrodicalcium citrate containing water of crystallization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |